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Module 3: Reproductive Tract Infections
Re p r o d u c t iv e  Tr a c t  In fe c t io n s
Le a r n in g  Ob je c t iv e s
This module is designed for reproductive health professionals inter­
ested in conducting surveillance and epidemiologic studies related 
to reproductive tract infections (RTIs) and who need a working 
knowledge o f epidemiologic and analytic issues specific to RTIs.
After studying the material in this module, the student should be 
able to:
• Identify the major viral and bacterial RTIs and their sequelae.
• Describe the interaction between reproductive tract infections 
and family planning, child survival, safe motherhood, and HIV 
prevention.
• Understand the general model for the spread o f infection and its 
implications in the control and prevention o f RTIs.
• Translate the general model for the spread of infection into practical 
biologic and behavioral determinants o f the spread o f infection.
• Describe how data from surveillance systems and epidemiologic 
studies can be linked to public health action to reduce the burden 
o f RTIs.
• Understand the major epidemiologic and analytic issues specific 
to RTIs.
• Describe the uses o f research and collected data, including the 
dissemination of findings.
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Case Study: Reproductive Tract Infections— Ethiopia
he prevalence of reproductive tract infections (RTIs) in Ethiopia is among
the highest in Africa. Despite a decrease in the prevalence of syphilis 
since the 1960s due to increased use of antibiotics, the number of cases 
of gonorrhea, chancroid, and lymphogranuloma venereum reported to the 
Ministry of Health increased three to five times between 1983 and 1990.
Recognizing the cultural, social, and economic barriers for women attending 
sexually transmitted disease (STD) clinics in the face of this growing public 
health problem, researchers became interested in exploring possibilities for 
interventions in health services routinely attended by Ethiopian women. A 
study was conducted among 542 women attending family planning clinics 
(FPCs) and 1,569 women attending gynecological outpatient departments 
(GOPDs) to examine the socioeconomic and cultural context of family 
planning and to determine the prevalence of certain RTIs, pelvic inflammatory 
disease (PID), and cervical cancer among both groups of women.
A full abdominal and gynecological examination, along with a questionnaire 
soliciting detailed demographic and lifestyle information, was administered to 
each woman in the study. Clinical examinations revealed that, although women 
attending FPCs had fewer symptoms than those attending GOPDs, they had 
more clinical evidence of past and present PID and more active infections 
requiring immediate treatment. Serological testing revealed that these women 
also had more evidence of exposure to STDs with higher titers indicative of 
active or present infection. Of particular concern, only 4% of women attending 
FPCs had no serological evidence of RTIs, and 64% had serological evidence 
of three or more different infections. Use of FPC services was found to be 
associated with higher levels of income and education; therefore, broadening 
educational opportunities for girls and women should increase acceptance of 
FPC services and bring about more opportunities for detection, treatment, and 
prevention of RTIs.
A significant implication of this study is that targeting women who attend 
FPCs for epidemiologic studies and control and prevention programs is an 
effective way to reach women who, for various reasons, may not attend STD 
clinics. The FPC visit provides an opportunity for screening women who are 
particularly at risk for infection and for educating women about modes of 
STD transmission and prevention of future infection. When treatment for 
RTIs can be offered in the FPC, women are not required to make separate 
visits to other primary health centers for care. On the basis of studies such 
as this one, adequate screening, treatment, and education of women attending 
FPCs and their partners should be considered as ways of easing the burden 
of RTIs in the community.
Adapted from: Duncan M E,Tibaux G, Kloos H, et al. STDs in women attending family planning clinics: 
a case study in Addis Ababa. Soc Sci M ed l9 9 7 ;4 4 (4 ) :4 4 l-5 4 .
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Ov e r v ie w  o f  Re p r o d u c t iv e  Tr a c t  In f e c t io n s
Reproductive tract infections (RTIs) include three types of 
infection: 1) sexually transmitted diseases (STDs), such as 
chlamydia, gonorrhea, chancroid, and human immunodeficiency 
virus (HIV); 2) endogenous infections, which are caused by 
overgrowth o f organisms normally present in the genital tract 
of healthy women, such as bacterial vaginosis or vulvovaginal 
candidiasis; and 3) iatrogenic infections, which are associated 
with improperly performed medical procedures such as unsafe 
abortion or poor delivery practices (1). RTIs are preventable, 
and many are treatable as well.
The burden o f untreated RTIs is especially heavy for women 
because these infections are often asymptomatic or the symptoms 
are not recognizable. Morbidity and mortality related to RTIs deprive 
society of important contributions made by women in terms of 
economic, social, and cultural development. Although RTIs affect 
women in both developing and industrialized countries, the 
infections and their sequelae are an especially urgent public health 
problem in resource-poor areas around the world. Demographic 
changes in developing countries have led to a dramatic increase in 
the number of adolescent and young adult women and men in their 
most sexually active years, which translates into a greater proportion 
of the population at risk for RTIs. The large number of infants 
and children in these countries means that this trend will continue 
for several decades. The risk o f RTIs is compounded by rapid 
urbanization and high male-to-female ratios in some regions (1).
The problems associated with RTIs have become even more signifi­
cant in the past decade with the emergence of H IV  and acquired 
immunodeficiency syndrome (AIDS).
Prevalence o f RTIs
Epidemiologic data show that the incidence and prevalence of 
various RTIs vary greatly between countries and even between regions 
within a country, a reflection of the differences in the characteristics 
of each pathogen (such as duration o f infectivity and transmissibility) 
as well as other biological, behavioral, medical, social, and economic 
factors (2). Among pregnant women in developing countries, it is 
estimated that gonorrhea rates are 10-15 times higher, chlamydia 
rates are 2-3  times higher, and syphilis rates are 10-100 times higher
3
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than the rates for these STDs among women in industrialized 
countries (1). However, because of differences in study design, 
reporting, specimen collection, and laboratory methods across the 
world, it is difficult to interpret data on the prevalence o f RTIs in 
developing regions in terms of internal validity or generalizability (1). 
Still, the data that are available suggest that RTIs are common in 
almost all of the developing countries in which they have been 
investigated. Rates of RTIs tend to be highest among high-risk 
groups such as commercial sex workers and clients of STD clinics, 
but are also prevalent in asymptomatic populations and low-risk 
women, such as those attending antenatal clinics (3).
W hat Are the M ost Commonly Occurring 
RTIs in Developing Countries?
Some of the more common bacterial infections occurring in develop­
ing countries include gonorrhea, chlamydia, syphilis, bacterial 
vaginosis (BV), lymphogranuloma venereum (LGV), trichomoniasis, 
and chancroid. Viral infections most common to developing coun­
tries include human papillomavirus (HPV), hepatitis B virus (HBV), 
herpes genitalis (herpes simplex virus [HSV], primarily type HSV-2), 
and HIV. The pathogens, symptoms, diagnoses, and treatment 
regimens for the most commonly occurring RTIs in developing 
countries are listed in Appendix A.
Sequelae o f Untreated RTIs
RTIs and their sequelae have widespread effects on the health and 
well-being of men, women, young people, and newborns. RTIs can 
pose a threat to a man’s fertility since certain untreated infections, 
such as Neisseria gonorrhoeae or Chlamydia trachomatis, can block 
the vas deferentia or cause epididymitis, an inflammation of the tubes 
through which sperm move from the testes to the vas deferentia. 
Although the dangers to men’s reproductive health must be recognized, 
women are clearly at greater risk o f infection and carry the greater 
burden o f the disease. Each year thousands of women die from the 
sequelae of undiagnosed or untreated RTIs, including cervical cancer, 
ectopic pregnancy, acute and chronic infections o f the uterus and 
fallopian tubes, and puerperal infections. Other sequelae include 
infertility, fetal wastage, low birth weight, infant blindness, neonatal 
pneumonia, and mental retardation. Table 1 outlines the major STD 
pathogens that produce RTIs, along with pregnancy-associated and 
chronic conditions caused by these pathogens.
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Table 1. Major STD Pathogens That Produce RTIs and Associated Conditions





























Haemophilus ducreyi Genital ulcer None known Impotence
H um an immunodeficiency 
virus (HIV)




H um an papillomavirus (HPV) Genital warts Laryngeal papillomatosis Genital cancer
Herpes simplex virus 2 (HSV-2) Genital ulcer Neonatal HSV 
Prematurity
Genital cancer




Adapted from: Brunham RC, Embree JE. Sexually transmitted diseases: current and future dimensions of the problem 
in the third world. In: Germain A, Holmes KK, Piot P, Wasserheit JN , editors. Reproductive tract infections: global 
impact and priorities for women’s reproductive health. New York: Plenum Press; 1992. p. 37.
Policymakers and health care professionals concerned about child 
survival must address RTIs because o f the significant role they play in 
fetal wastage, low birth weight, and congenital and perinatal infec­
tions. The impact of RTIs on pregnancy depends upon the pathogen 
involved, the chronicity o f infection, and the stage of gestation during 
time of infection (1). In general, RTIs appear to pose a much greater 
problem in pregnant adolescents than in older pregnant women, who 
are more likely to be involved in a stable, monogamous relationship at 
the time o f conception (4). The availability o f inexpensive, efficacious 
interventions for several RTIs during pregnancy has led to increased
5
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Com plications and Sequelae of Reproductive 
Tract Infections and HIV
fyelvic inflammatory disease (PID) A potentially life-threatening condition resulting from complications 
of N. gonorrhoea and C. trachomatis infections. PID 
comprises a spectrum of inflammatory disorders of the 
upper female genital tract, including any combination of 
endometritis, salpingitis, tubo-ovarian abscess, and pelvic 
peritonitis. PID increases the risk of tubal infertility, ectopic 
pregnancy, and chronic abdominal pain.
Tubal infertility Associated with PID and results from 
inflammation and scarring of the fallopian tubes following 
ascent of gonorrhoea, chlamydia, and possibly bacterial 
vaginosis organisms into the upper reproductive tract.
Tubal occlusion prevents the egg from passing through 
the fallopian tubes.
Ectopic (tubal) pregnancy A potentially fatal condition 
that results when a fertilized egg implants outside the uterus, 
usually in the fallopian tubes.This type of pregnancy occurs 
when an ascending infection in the reproductive tract partially 
blocks tubal passages.
Genital cancers Potentially fatal diseases that have been 
associated with RTIs. Certain types of human papillomavirus 
(HPV) are associated with the development of cervical neoplasia.
Chronic pain May be experienced by patients with RTIs 
such as genital herpes and PID, which may cause persistent 
or episodic genital or abdominal pain.
Spectrum o f HIV/AIDS symptoms Over the course of 
HIV infection, potentially the most serious RTI; the spectrum 
of symptoms includes acute retroviral illness, sore throat, 
swollen lymph nodes, increased skin rashes, herpes zoster, 
pulmonary tuberculosis, diarrhea, chronic fever, severe weight 
loss, bacterial pneumonia, invasive cancers, debilitating fatigue, 
simultaneous and recurrent infections, and, ultimately, death.
Adapted from: CDC. Family planning methods and practice: Africa. 2nd edition. 
Atlanta (GA): United States Department o f  Health and Human Services, CDC; 
1999.
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awareness of the avoidability o f adverse outcomes of pregnancy.
Table 2 shows the proportion o f pregnant women experiencing 
adverse outcomes by maternal diagnosis.
Table 2. Proportion o f  Pregnant W om en Experiencing Adverse Outcomes
Maternal Diagnosis Fetal Wastage Low Birth Weight Congenital or
or Prematurity Perinatal Infection
% % %
C hlam ydia................................................................... rare 10—30 40—70
G onorrhea................................................................... rare 11—25 30—68
Early syphilis...........................................................  20-25  15-50 40-70
Genital herpes
Prim ary..................................................................7 -5 4  30-50  30-35
Recurrent................................................................rare rare 0.4-8
Bacterial vaginosis...................................................... rare 10-25 rare
Trichom oniasis...........................................................rare 11-15 rare
No R T I........................................................................4 -10  2 -1 2  NA
Adapted from: Wasserheit JN , Holmes KK. Reproductive tract infections: challenges for international health policy, 
programs, and research. In: Germain A, Holmes KK, Piot P, Wasserheit JN , editors. Reproductive tract infections: 
global impact and priorities for women’s reproductive health. New York: Plenum Press; 1992. p. 16.
How Are RTIs Transmitted?
RTIs are caused by bacterial, parasitic, and viral pathogens. Gener­
ally, the pathogens causing RTIs enter the body through the mucous 
membranes during unprotected vaginal, anal, or oral intercourse with 
an infected partner (5). An individual’s risk o f contracting an RTI or 
developing sequelae o f an RTI is a function of five components: the 
risk o f interaction with an infected person who may become a regular 
sex partner; exposure to the infection of that partner; acquisition of the 
RTI when exposed; development of a symptomatic RTI if infected; 
and development of the sequelae following the RTI (6). The same 
sexual behaviors may result in the acquisition of different RTIs, 
depending on which infections are most prevalent in a particular setting.
Multiple infections within the same individual are also frequent, as is 
reinfection if partners have not been adequately treated.
For many STDs, the probability of transmission is higher from 
males to females than from females to males. Most STDs tend to 
exhibit a “biological sexism” (7); in other words, anatomic factors 
appear to make the transmission o f STDs more efficient from male 
to female than from female to male. For example, the risk o f acquir­
ing gonorrhea from a single sex act (where one partner is infectious)
7
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W hy do STD s affect 
women more severely 
than men?
Wf  omen are less able to prevent exposure to 
STDs than men largely 
because of the lack of 
female-controlled barrier 
methods and because 
women are often limited 
in their ability to negotiate 
the conditions under which 
intercourse occurs. Women 
are more likely than men to 
acquire STDs from a single 
sexual encounter since 
women have a larger 
surface area exposed 
during intercourse and 
longer contact time with 
pathogens compared with 
men. When transmission 
does occur, women are more 
likely than men to be 
asymptomatically infected 
and, as a consequence, 
are less likely to recognize 
symptoms and seek health 
care. Even when health care 
is sought, most STDs are 
more difficult to diagnose 
in women than in men. 
Furthermore, the potential 
for spread of infection to the 
upper genital tract (e.g., the 
uterus and fallopian tubes 
or the testicles) is greater 
in women than in men.
Lastly, women tend to suffer 
more serious long-term 
consequences than men, 
including pelvic inflammatory 
disease, infertility, ectopic 
pregnancy, chronic pelvic 
pain, and cervical cancer.
is approximately 25% for men and 50% for women (7). Infections 
tend to occur at an earlier age in females and affect females more 
severely than men.
RTIs can also be transmitted from the mother to the fetus during 
pregnancy or to the newborn at delivery. Most adverse outcomes 
occur before birth or during the first 30 days after birth (8). Syphilis 
during pregnancy has been shown to cause infant death, adverse 
outcome, or syphilitic infants in more than 5% of cases where 
the pregnancy survives beyond 12 weeks. Gonococcal ophthalmia 
neonatorum occurs in 2% -6%  of newborns. Table 3 shows the 
prevalence, rate o f transmission from mother to child, and manifesta­
tions o f selected RTIs.
How Are RTIs and Their Sequelae Linked W ith 
Key Health-Related Developm ent Programs?
A major challenge facing women with RTIs in developing countries 
is limited access to health care for those infections. Concepts o f case 
management used in developed countries are usually inappropriate 
for implementation in developing countries in which care is provided 
through an array of services and individuals (3). In many parts o f the 
world, women rely heavily on reproductive health services, particu­
larly family planning and maternal/child health (FP/MCH) services, 
for most of their health needs. Other services attended by women 
include primary health care centers, general hospital outpatients, 
and private practice. A considerable amount of treatment for RTIs 
is offered by pharmacists, traditional healers, untrained lay people, 
and street vendors.
Most of the services attended by women in developing countries 
lack skilled personnel and access to the drugs required to detect and 
treat RTIs. The majority o f clinics that are equipped to manage these 
infections primarily gear their services toward men. A response to 
these issues was the recommendation for the integration of preven­
tion and treatment services for RTIs into other reproductive health 
services routinely attended by women, including family planning 
and prenatal clinics.
Serving women in the general population through existing health 
programs has become an essential part o f RTI prevention and 
control. RTIs are an integral part o f fundamental health-related 
development programs, such as these concerned with family plan­
ning, child survival, women’s health, safe motherhood, and 
HIV prevention (see Figure 1, p. 10) (1).
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Table 3. Prevalence, Transmission Rates, and M anifestations o f  Selected RTIs
RTI Prevalence o f Infection Fetal/Neonatal 
in Pregnant Women Transmission Rate
Adverse pregnancy 
outcomes caused by 
syphilis; Treponema 
pallidum
0.03% -0.3%  in 
industrialized countries; 
3% -22%  in Africa, 
parts of South America, 
and Fiji
Overall, 40% —70%; 
almost 100% if  maternal 
syphilis is early stage; 













Low: 1% or less, such as in 
Western Europe and some 
parts of N orth America 
High: 4% -20% , such as 
in sub-Saharan Africa 
and Thailand
47%; 68% when 
concomitantly infected 
w ith Chlamydia 
trachomatis
Total: 60% -70%  
Conjunctivitis: 15%—50%; 
15%—30% severe,
25% coming to medical care
Pneumonia: 5%—15%;
5% coming to medical care
Primary infection: 50% 
Recurrent infection: 
0.4% -8%
Incidence o f the 
Manifestation 
W ithout Interventions
At a seroprevalence of 10%, 
over 5%  of all pregnant 
women would have an 
adverse outcome: 2% 
spontaneous abortions; 
2.4%  perinatal deaths; and 
1.4% syphilitic infants.
4% -6%  of births in Africa; 
2% -4%  common in much 
of Africa.
Assuming a 10% 
seroprevalence, 2.5%  of 
pregnancies would result in 
infants with conjunctivitis 
who are brought to 
medical care.
Assuming a 10% 
seroprevalence,
0.5% of pregnancies would 
result in infants with 
pneumonia.
Incidence is 0.2% —0.33% 
per 1,000 live births in the 
United States, with overall 
mortality of 0.14% —0.23% 
per 1,000 live births.
Range: 2% —37% 
Common: 4% —l2%  
Low: 0% -5%  
Medium: 6%—14% 
High: 15% and higher




High: 15% and higher
20% -50%  in the United 
States have developed 
antibodies to HSV; 
viral excretion at delivery 
is approximately 0.01% — 
0.39%; prevalence appears 
lower in other parts of 
the world
H IV  Industrialized countries:
15% -25%
Developing countries:
_____________________________________________________ 25% -45% _____________________________________________
Adapted from: Schulz KF, Schulte JM , Berman SM. M aternal health and child survival: opportunities to protect both 
women and children from the adverse consequences o f reproductive tract infections. In: Germain A, Holmes KK, Piot 
P, Wasserheit JN , editors. Reproductive tract infections: global im pact and priorities for women’s reproductive health. 
New York: Plenum Press; 1992. p. 146.
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Each of these health programs provides a critical opportunity for 
the prevention, detection, and control of RTIs with excellent oppor­
tunities to educate clients about modes o f RTI transmission and 
prevention of future infection.
There can be serious limita­
tions to integration, includ­
ing an overemphasis on 
clinical management of STDs 
accompanied by significant 
problems in implementing 
clinical management proto­
cols, as well as a lack of 
support for primary preven­
tion, such as condom 
promotion and behavioral 
change interventions (9).
A review that tried to clarify 
the public health benefits of 
integration found some 
evidence to suggest that 
where there was an emphasis 
on STD prevention, the 
quality of services, providers’ 
attitudes, and communica­
tion skills improved (10). 
However, there was inad­
equate evidence to show 
increased use o f STD 
treatment services or an impact on STD rates. Because o f these 
limitations o f past efforts at integration, some guidelines have advo­
cated for a focus on primary prevention (e.g., counseling and behavior 
change interventions, aggressive condom promotion, and social 
marketing) as well as prevention and treatment efforts targeted at “high 
transmitters,” those most likely to contract and transmit STDs (9).
Figure 1. The Role o f  RTIs in  Health-Related  
Developm ent Programs
Source: Wasserheit JN , Holmes KK. Reproductive tract infections: 
challenges for international health policy, programs, and research.
In: Germain A, Holmes KK, Piot P, Wasserheit JN , editors. Reproductive 
tract infections: global impact and priorities for women’s reproductive 
health. New York: Plenum Press; 1992. p. 8.
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Guidelines on when to integrate clinical STD or RTI management 
into FP/M CH programs highlight how epidemiology can be used to 
guide programmatic decisions (9). (See “Integrating STD Clinical 
Services Into Family Planning and Maternal/Child Health Pro­
grams,” p. 12.) The first steps are to determine the prevalence of 
various STDs in the FP/M CH population and to conduct drug 
sensitivity studies. These steps are critical in determining whether 
these services will have a public health benefit. The positive predictive 
value of any screening or diagnostic test will be higher in communi­
ties where the infection is more prevalent. The second step, assessing 
the risk profile of clientele who use the particular FP/M CH service 
delivery setting, can be done through risk assessment surveys of 
clients.
Family Planning Services Provide an Opportunity 
to Treat Asym ptom atic Genital Tract Infections 
in Rural South Africa
A study was conducted among women attending the family planning clinic at Hlabisa Hospital, South Africa, to determine the prevalence 
of asymptomatic and unrecognized genital tract infections (11). As part 
of the study, women attending the family planning clinic were offered a 
gynecologic examination during which a vaginal swab and questionnaire 
were administered. Diagnostic testing of the swabs revealed that 119 
(63%) of the 189 women had at least one infection and 49 (26%) 
had multiple infections. Of the 66 women with gonorrhea, chlamydial 
infection, trichomoniasis, or bacterial vaginosis, 35 (53%) were 
asymptomatic. Furthermore, many symptomatic women failed to 
recognize and report their symptoms. Results also revealed that 15 (8%) 
of the women had active syphilis and 44 (24%) tested positive for HIV. 
None of these cases were detected during routine family planning 
consultations, mainly because syphilis screening and HIV testing were 
not done by the family planning service, on-site microbiological facilities 
were unavailable, and many cases of infection were asymptomatic. 
Family planning providers in this setting could consider incorporating 
routine syphilis screening and HIV testing into existing services as a 
strategy to reduce the burden of RTIs in this setting.
11
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Integrating S T D  Clinical Services Into Family 
Planning and Maternal/Child Health Programs
Before integrating clinical STD services into FP/MCH programs, program managers should take the following
minimum steps:
1. Determine the prevalence of various STDs in the FP/MCH 
population. Laboratory screening tests suitable for prevalence 
surveys are increasingly available and possess high sensitivity 
and specificity.The cost of these surveys is not excessive and 
sample sizes o f200-300  service delivery clients may be 
sufficient to guide decision making about locating and targeting 
integrated services.The prevalence of gonorrhea and chlamydia 
in typical FP/MCH settings in Africa is 6%-l0%.
2. Assess the risk profile of clientele who use the FP/MCH service 
delivery setting. Integration of clinical STD services may be 
more justifiable in settings that serve a higher proportion of 
clients at high risk (e.g., commercial sex workers and their 
partners). Simple instruments can be used to determine basic 
demographic information and assess level of risk behavior.
3. Ascertain the level of staff expertise and available 
infrastructure.
4. Ensure that integrated FP/MCH interventions will receive 
necessary training, supervision, technical standards, and other 
organizational support to ensure that the quality of services 
delivered remains high.
5. Ensure that sufficient resources are available, especially for STD 
drugs, because STD drug procurement is not one of USAID’s 
comparative advantages.
Adapted from: USAID. Integration o f  family planning/MCH with HIV/STD prevention.
Washington: USAID; December 1998.
v_______________________________________________y
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G e n e r a l  M o d e l  o f  t h e  
E p i d e m i o l o g y  o f  RTIs
Epidemiology is used for measuring the distribution and determi­
nants of health and illness in a population and for applying this 
information to the detection, prevention, and control of disease. 
Prevention and control of RTIs are made possible through surveil­
lance and epidemiologic studies o f disease etiology and transmission 
dynamics, treatment options, and intervention effectiveness. These 
studies help to explain the difference in risk of RTI among individu­
als within the same population and compare variations in the deter­
minants of disease between populations (12). Although biomedical 
research may explain why an exposure or behavior causes or prevents 
RTIs at the individual level, epidemiology adds to our understanding 
of the magnitude o f the exposure/disease relationship in groups of 
individuals (13). In some instances, such as HIV, epidemiologic 
research has provided information that has formed the basis for 
public health action long before the basic biologic mechanism of 
a particular disease was understood.
In some countries, epidemiologic studies provide information 
on the frequency of one or more RTIs in specific population groups. 
However, most of these studies are cross-sectional and provide infor­
mation on the prevalence rather than the incidence of infection. 
Prevalence studies count all individuals within a population who 
have had the health problem at a specified point in time, regardless 
of the length of time the individuals have had the problem. In con­
trast, incidence studies aim to measure only the number of new cases 
of a health problem in a population within a specified period of 
time. One technique for estimating the actual magnitude o f a health 
problem in a specific high-risk population is to exclude persons not at 
risk, since the overall incidence or prevalence rate may underrepresent 
the true extent of the disease in a particular subpopulation. For 
example, data for prevalence studies o f STDs are often collected from 
a high-risk population, such as clients of STD clinics or commercial 
sex workers, and care should be taken in extrapolating from these 
studies to the general population (14).
How Is the Spread o f RTIs Measured?
At the population level the rate of spread o f STDs and RTIs is 
dependent on the average number o f new cases generated by each 
infected individual. A number of biological characteristics o f RTI 
pathogens influence the rate at which they spread and the usefulness 
of various control strategies (15). The average rate of infectiousness 
also depends on the quality, accessibility, and uses of health services.
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Transmission 
dynamics of STD s  
are approximated by
R0 = PcD
where p is the average 
probability that the 
infection is transmitted 
per sexual partner 
contact per unit of time 
(efficiency of transmis­
sion), c is the average 
number of sexual 
partners per unit of time, 
and D is the average 
duration of infectiousness 
of an infected individual. 
The higher the value of 
R0, the greater the 
potential for the spread 
of an STD. For an 
epidemic to occur,
R0 > I .
The average number of new cases generated by each infected indi­
vidual is termed the basic reproductive rate of infection, or R0. The 
basic reproductive infection rate is determined by the average prob­
ability that infection is transmitted from an infected individual to a 
susceptible individual (P), the effective mean rate o f sexual partner 
change (c), and the average duration o f infectivity (D).
The amount by which an infection’s reproductive rate exceeds (or is 
below) 1.0 determines how rapidly the infection will spread (or be 
eliminated) in the community (15). Although this measurement 
of reproductive success has many limitations, it is an important 
concept because the magnitude of reproductive success determines 
the pattern of infection and the rate at which an infection spreads 
when introduced into a susceptible population (16). This model of 
STD transmission has been used to make predictions about epidemics 
and to specify factors that determine the rate of transmission or the 
process leading from initial infection to disease (17).
Efficiency o f Transmission (P)
The efficiency of transmission (P) depends on the infectiousness 
of the pathogen, the infectivity of the infected individual, the suscep­
tibility of the host, and the type of sexual act (e.g., vaginal, anal, 
or oral). For example, the use o f barrier methods o f contraception 
decreases the susceptibility of the host to infection, thereby decreasing 
the efficiency o f transmission of many RTIs. Efficiency of transmis­
sion is also related to the size of the pathogen and is generally highest 
during early infection and when lesions or exudate are present. Other 
biological factors may also increase the risk that a susceptible person 
will acquire an RTI after exposure. For example, cervical ectopy 
(a process of squamous metaplasia that begins at menarche, in which 
the columnar epithelial cells around the cervical os are replaced by 
squamous epithelium) has been shown to increase the risk o f chlamy­
dial and gonorrheal infection (2). Since cervical ectopy decreases 
as a woman ages and increases with oral contraceptive use, very 
young women and oral contraceptive users may be at higher risk 
of infection.
Effective Mean Rate o f Sexual Partner Change (c)
The basic reproductive infection rate in a population depends on 
the average number of sexual partners per person per unit of time, 
heterogeneity (differences) in rates of sexual partner change, patterns 
of sexual contact (i.e., who mixes with whom), and the types of 
contraceptives used and how they are used. In general, people with 
high rates of sexual partner change contribute disproportionately 
to the transmission of RTIs; however, rates o f sexual partner change 
depend on many demographic and social factors.
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Duration o f Infectiousness (D)
Early detection and treatment reduces the average length o f time 
infected individuals are infectious and therefore reduces both the 
rate o f spread o f the infection as well as the probability that infected 
individuals will develop complications and sequelae (2). The infec­
tiousness of a particular individual is subject to great variation with 
respect to both duration and intensity (16).
How Is the Model o f Transmission 
Dynamics Applied?
The variables in the transmission dynamics model can be translated 
into practical determinants of the spread of infection. For example, 
transmissibility of infection is influenced by behavioral factors such as 
the number of partners and susceptibility to infection is influenced by 
the use of barrier methods such as condoms. By clarifying demographic 
and social correlates of RTIs, women with increased risk of infection 
may be identified through routine screening, and measures can be taken 
to control and prevent the spread of infection in the population. Table 4 
provides examples of biological, behavioral, medical, and social and 
economic factors affecting the spread of STDs and RTIs.
Table 4. Factors Affecting the Spread o f  STD s and RTIs in  a Population
Variable Affected
Biological
Duration o f infectivity.................................................................................................................................................  D
Presence of other S T D s ................................................................................................................................................  P
Infectivity o f particular strain of the pathogen ......................................................................................................  P
Age and presence of cervical erosion.......................................................................................................................... P
Immunologic s ta tu s .......................................................................................................................................................  P
Circumcision s ta tu s .......................................................................................................................................................  P
Behavioral
Rates o f sexual partner change.......................................................................................................................................c
Type o f sexual intercourse (anal, oral, vaginal) ....................................................................................................... P
Use of condoms and other contraceptives ........................................................................................................... P, c
Patterns of sexual contact and m ixing..........................................................................................................................c
Medical
Access to health care facilities....................................................................................................................................  D
Access to laboratory facilities...................................................................................................................................... D
Availability o f appropriate trea tm en t.......................................................................................................................  D
Social and Economic
M igration patterns ........................................................................................................................................................... c
Ease of trav e l......................................................................................................................................................................c
Level of education ............................................................................................................................................................ c
R eligion............................................................................................................................................................................... c
Civil unrest......................................................................................................................................................................... c
Position of women in society......................................................................................................................................... c
Adapted from: Rowley J, Berkley S. Sexually transmitted diseases. In: Murray CJL, Lopez AD, editors. Health 
dimensions o f sex and reproduction. Boston: Harvard University Press; 1998. p. 27.
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The basic reproductive rate of infection (Rq) model can be used as 
a tool for identifying the relative influences of different behavioral, 
biological, medical, and socioeconomic components on the rate at 
which different people acquire infection and has implications for the 
design and implementation of control and prevention programs. For 
example, infections that are transmitted more efficiently may contrib­
ute to rapid increases in the incidence of RTIs through the activities 
of potential high-frequency transmitters such as prostitutes (15). In 
these cases, control efforts that reduce transmission by core group 
members may rapidly affect the incidence of those RTIs.
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Lo n g -Te r m  Ou t c o m e  In d ic a t o r s  
f o r  STDs AND RTIs
Indicators are measurements that, when compared with either 
a standard or desired level of achievement, provide information 
regarding a health outcome of a management process. Useful 
indicators serve as markers of progress toward improved reproductive 
health status, either as a direct or proxy measure of impact (outcome 
indicator), or as a measure of progress toward specified process goals 
(process indicator) (18). This discussion will focus on outcome 
measures that reflect changes in mortality, morbidity, and other 
health outcomes.
Conceptually, the long-term goal of RTI control and prevention 
programs is improved reproductive health at the population level, 
but it is often difficult to link changes in long-term indicators directly 
to a particular intervention program. For this reason, many evalua­
tions are limited to simply monitoring change in key indicators 
over time (19). Researchers interested in using indicators to evaluate 
specific programs should choose those most relevant to the objectives 
of the program. The following indicators provide examples of types of 
measures useful in monitoring progress toward reduction o f HIV, 
STDs, and RTIs (19):
w4
RTI Prevalence in a Defined Target Population
Definition. This measure is defined as the number of persons 
diagnosed with a specific RTI or syndrome at a given point in 
time per 100,000 persons in the population (or population sub­
group, defined by such characteristics as age, gender, and place of 
residence) and is calculated as follows:
Number o f RTIs identified by syndromic 
signs/symptoms or 
etiologic (serologic/culture) methods
-----------------------------------------------------------  x 100,000
Number of people in population group screened or 
covered by case reports
Data sources for the numerator include special laboratory-based 
surveys, sentinel surveillance, and case (syndromic or etiologic) and 
laboratory reports from clinicians and diagnostic laboratories. When 
the numerator is found through special laboratory-based surveys or 
sentinel surveillance, the denominator is the number o f people 
screened. If the numerator is the number of case and laboratory
17
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reports from clinicians and diagnostic laboratories, the denominator 
is the number of people in the population (or population subgroup) 
served by the reporting facilities.
Use and Interpretation. It is important to emphasize that this is a 
measure o f prevalence rather than incidence and provides an estimate 
of the current situation regarding RTIs in the sample population for 
the period o f testing. In some settings, however, this indicator can 
resemble a measure of incidence. For example, in Sweden the level 
of gonorrhea has been controlled for nearly 30 years. In this setting it 
is highly likely that any cases reported in a recent calendar year would 
be new cases; thus, the calculation o f prevalence may approximate 
the incidence rate of gonorrhea. The use of cross-sectional surveys 
to determine the prevalence of RTIs is generally considered the best 
method since it is possible to define the population at risk by control­
ling the sampling frame, and to avoid many of the biases inherent to 
other methods (for example, sentinel surveillance and case reporting 
methods); however, this method requires considerable infrastructure 
(laboratory and statistical) and resources.
Infertility
Definition. This measure is defined as the proportion o f sexually 
active noncontracepting women in a reproductive age group (usually 
15-45 years) at risk of pregnancy who have not had any pregnancies 
in the previous 5 years and is calculated as follows:
Number of women in the specified age group who are 
not using contraceptives (and have not done so in the 
past 5 years), are not pregnant, and have not had a 
child in the last 5 years
--------------------------------------------------------------------------- x 100,000
Total number of women in the specified age group 
who are at risk of pregnancy (i.e., those who are not using 
contraceptives, and are not pregnant)
Data sources for estimating infertility include the Demographic 
Health Survey data and fertility surveys.
Use and Interpretation. This indicator measures the level of infer­
tility in a community. A level of 5% or less is to be expected in all 
populations because of inherent reproductive abnormalities. The 
most common cause of increased rates of tubal infertility in many 
countries is STDs. For example, the proportion of infertility attribut­
able to RTIs is 50% -80%  in Africa, 15%—40% in Asia, 35% in
18
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Latin America, and 10%—35% in industrialized countries (1). 
Therefore, to some extent this indicator is a measure of consequence 
of STD in a community. The period of 5 years is a generous time 
interval since it is generally accepted that 90% of all couples will 
achieve pregnancy within 2 years if they have regular intercourse 
and do not use contraception.
STD/HIV-Related Cause-Specific M ortality Rate
Definition. This indicator combines four life-threatening diagnoses 
related to STD /HIV  into one measure of mortality. It is an estimate 
of the STD/HIV-related cause-specific death rate among women of 
reproductive age due to four leading causes: AIDS; cervical cancer 
due to HPV; PID; and ectopic pregnancy. This indicator is calculated 
as follows:
Number o f deaths among women aged 15—49 years due 
to AIDS; cervical cancer due to HPV; PID; and 
ectopic pregnancy
-------------------------------------------------------------------------- x 100,000
Total number o f women aged 15—49 years
The data source for this measure is hospital records indicating cause- 
specific mortality among women of reproductive age.
Use and Interpretation. This measure underscores the idea that 
the long-term goal of STD /HIV  intervention programs is to lower 
mortality by reducing the risk of exposure to infection. However, 
programs are not usually evaluated by this measure because it is 
virtually impossible to separate the effects o f program intervention 
from other external factors (such as socioeconomic conditions) on 
this outcome. Furthermore, behavioral changes leading to reductions 
in STD /H IV  incidence will require several years to have a noticeable 
impact on this mortality rate.
Prevalence rates of these four diseases may vary across countries, and 
those diagnoses that are most life-threatening in a region should be 
given special consideration. Also, the ability to diagnose certain 
infections may vary depending on the medical technology available 
in a region, or whether etiologic testing or the syndromic approach 
is used to detect infections. The mortality rate may appear to increase 
in areas in which screening services are improved because o f better 
case detection. This indicator may be adapted to specific age groups 
(e.g., 15—24, 25—34, 35 years and older) to enhance its cultural or 
geographical relevance.
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Rate o f Congenital Syphilis or 
Ophthalmia Neonatorum
Definition. This indicator is the number of infants born infected 
with syphilis or with gonococcal/chlamydial eye infections during 
a specific time period (usually one year) per 100,000 live births.
This indicator is calculated as follows:
Number of cases of infants born with 
congenital syphilis (CS) or ophthalmia neonatorum (ON)
-----------------------------------------------------------------------------  x 100,000
Number o f live births among population covered 
by case reports
The data sources for the numerator include case and laboratory 
reports from clinicians, clinical settings, and diagnostic laboratories. 
Vital records serve as the data source for the denominator.
Use and  Interpretation. Theoretically this measure could be used 
as a marker of STD at the population level. However, there are 
significant diagnostic problems associated with case definition of 
CS and ON, especially in resource-poor settings. The appropriate 
diagnostics may not be universally applied to all births, resulting in 
underdetection of cases. For congenital syphilis, the most appropriate 
diagnostics relate to the mother. Syphilis prevalence data for pregnant 
women provide information about both latent and symptomatic 
syphilis in this group and minimize the problems associated with 
general reporting of RTIs. Because the primary lesion is often painless 
and secondary syphilis is usually not diagnosed, women are mainly 
identified through serological screening. As with all case reporting 
systems, the quality of the data is influenced by the providers 
who make the diagnosis and the system of health statistics and 
infrastructure.
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S u r v e i l l a n c e  f o r  RTIs
Surveillance is an essential component of effective prevention and 
control programs for RTIs and is used to determine the need for 
public health action and assess the effectiveness of interventions and 
programs. Surveillance is an important means o f obtaining baseline 
information before establishing RTI services. It is also a mechanism 
for collecting the information needed to calculate the long-term 
indicators discussed earlier. Ongoing surveillance is used to identify 
temporal trends in RTI morbidity and is often used to guide decisions 
regarding the allocation of resources for control and prevention programs.
m
Surveillance for STD s in the Russian Federation
A state system for the control and surveillance of STDs in which diagnosis, treatment, and partner notification are provided 
by clinical Dermatovenereology Service dispensaries has existed 
in the Russian Federation since World War II (20). In 1993, the 
notification by physicians of newly identified cases of nine STDs 
(syphilis, gonorrhea, trichomoniasis, urogenital chlamydiosis, human 
papillomavirus infection, genital herpes, mycoplasmosis, candidiasis, 
and bacterial vaginosis) was mandated. Through this system of 
surveillance, researchers noticed a 63-fold increase in the rate of 
syphilis from 1993 to 1997. Although improvements in laboratory 
techniques for diagnosis have been suggested as the reason for this 
apparent increase, it is also likely that the cause is related to the 
economic and political changes occurring in the Russian Federation. 
Shifts in living standards, working conditions, health services funding, 
and migration rates, and changes in social infrastructure following 
the breakup of the Soviet Union are factors that may affect the 
occurrence of syphilis. Of particular concern is the high rate of 
syphilitic morbidity among children and adolescents— 26,000 cases 
were reported in 1997. These population-based findings are 
especially relevant for public health officials, who must base their 
control and prevention strategies on estimates of the burden of 
STDs and their distribution within the population.
Reporting cases may be mandatory or voluntary, but ideally every 
country should have an active RTI surveillance system to which cases 
of disease are reported. In countries that have good vital registration 
and reporting systems, the number of reported cases is a reliable 
proxy for the total number of infections of disease with very definite 
symptoms (2). Sources of information include medical records, health
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care facilities, commercial and reference laboratories, and research 
projects. In general, specialty STD clinics tend to be the most reliable 
at reporting cases o f infection, followed by government facilities and, 
lastly, private practitioners (2).
Rapid assessment is another important method for collecting data 
that uses a similar methodology and is fraught with many of the same 
issues as surveillance. Unlike surveillance, which is ongoing, rapid 
assessment is an accelerated form of epidemiologic research used 
to determine the prevalence of a condition at a point in time and 
rapidly link the information to public health action. In some situations 
this method is preferable to conventional epidemiologic research 
approaches, which can be time-consuming and often lack the capacity 
to inform policy or program decision making in time. Rapid assessment 
may be especially important in acute emergency or crisis situations 
where timely interventions are necessary to improve the reproductive 
health of women.
Performing a Rapid Assessm ent for S TD s in a Rwandan Refugee Cam p in Tanzania
/n the aftermath of the genocide of Rwanda in 1994, more than 300,000 people crossed the border with Tanzania within a few weeks and were confined in two camps in northwest Tanzania.The 
disintegrating social structure was conducive to the transmission of STDs and HIV. During the initial 
phase of the refugee camps, there was little data on the prevalence of STDs. Information was needed 
to target STD service delivery more efficiently (21).
In a weeklong rapid assessment, 100 women attending one antenatal clinic were given a full 
physical and gynecological examination, during which vaginal swabs were collected for immediate 
wet preparation and gram staining, cervical swabs were collected for Neisseria gonorrhoeae (NG) 
culture, and blood samples were collected for syphilis serology. STD indicators were validated against 
a confirmatory laboratory test indicating the presence or absence of STD. All patients found to have 
a vaginal discharge were treated upon first visit. Results of syphilis serology were communicated 
privately, and treatment was provided 2 weeks after the initial visit.
Results of the rapid assessment revealed that the prevalence of RTIs in these women was 60%, if 
candidiasis and bacterial vaginosis were included. It was also found that 60% of women who had an 
abnormal vaginal discharge upon examination actually reported a symptom related to genital discharge 
syndrome (discharge, genital itching, lower abdominal pain, dysuria, or dyspareunia), showing a good 
correlation between reported symptoms and confirmed signs. Women should be encouraged by clinic 
staff to report genital symptoms. Etiological diagnosis solely by type of discharge is not recommended—  
for example, all three women infected with NG were also infected by Trichomonas vaginalis, so 
symptoms for each infection could not be separated. It is important that all health-delivery staff be 
aware of how to recognize STDs in emergency settings. Rapid STD assessment can be useful in 
obtaining quick and reliable information at a relatively low cost. In this situation, results of the 
assessment provided a basis for case projection and budget planning. A second rapid assessment 
will be conducted later to evaluate the impact of these changes.
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Surveillance and rapid assessment surveys are useful tools for obtain­
ing information to guide public health efforts to reduce morbidity 
and mortality associated with RTIs. Determining the level of morbid­
ity in a population has important implications for influencing STD/ 
RTI program activity (22). Three epidemiologic measures o f disease 
frequency are commonly used: case counts, proportions, and inci­
dence. These measures are useful for calculating the long-term out­
come indicators discussed earlier. For accuracy of all measures of 
disease frequency, care must be taken in distinguishing between 
incident, prevalent, and recurrent infections.
/  \
Im portant Definitions in Measuring 
Disease Frequency
Incidence o f disease The number of new cases of the 
disease of interest occurring in a population during a defined 
time interval.
Prevalence o f disease The proportion of people in a 
population who have the disease of interest at a specified 
point in time.
Recurrence o f  disease Diagnosis of the disease of interest 
after receiving adequate treatment for this same disease.
\ ___________________________________________________________________________
Case Counts. Perhaps the simplest way o f reporting morbidity is to 
report the number of cases identified by counting the number of new 
(incident) or existing (prevalent) cases of the disease in the population 
during a given period of time. However, a count does not provide any 
information about the size o f the population in which the cases were 
identified and, thus, is often referred to as “numerator” data. Counts 
may be valuable in a particular population for allocating limited 
resources. For example, a large number of cases of a particular RTI 
identified in the community may require program personnel to direct 
program resources toward treating those cases and preventing spread 
of infection to others in the community.
Proportions. A proportion is defined as a fraction in which the 
numerator is included in the denominator. The numerator of a 
proportion is generated through case counts. Some previously de­
scribed measures, such as the STD/HIV-related cause-specific mortal­
ity rate and the rate o f congenital syphilis, are examples of propor­
tions. A proportion at a particular point in time is often expressed as 
a percentage (for example, clients who are appropriately managed for 
RTIs in a given month divided by all clients seen in that month).
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Proportions are used in a wide range o f public health activities. For 
example, if a large proportion of the reproductive morbidity in a 
community is associated with a particular RTI, program personnel 
may decide to concentrate outreach activities, expand clinic facilities, 
or work with community-based organizations in that area to reduce 
the burden of morbidity in the community due to that infection. In 
terms of RTI prevention and control, prevalence is a proportion that 
measures how widespread an infection is in a population, the amount 
of infection that needs to be treated in a population, and how much 
of that population may experience adverse sequelae if the disease is 
untreated or not treated in a timely manner.
Incidence Rates. An incidence rate is a measure of risk and the most 
common way of measuring frequency of disease in populations. This 
measure is a fraction in which the numerator is the number of people 
that develop a disease during a given time period (new cases), and the 
denominator is the population at risk for the disease during the same 
time period. (Note that in settings with stable prevalence o f infection, 
it is likely that any cases reported in a recent calendar year would be 
new cases; thus, the calculation of prevalence may actually approxi­
mate the incidence rate.) Incidence rates are useful for comparing the 
risk of disease between populations because they relate the number of 
new cases in each community to a population base. For many RTIs 
and STDs, the population at risk (denominator) would include only 
those people who are sexually active, a subgroup that is often difficult 
to identify. Obtaining accurate numerator and denominator data can 
be quite challenging but is an essential part of increasing awareness 
about the magnitude, sequelae, and preventability o f RTIs.
An accurate assessment of the dimensions of a problem enables 
policy and decision makers to focus their attention and resources 
on measures to control and prevent the spread of disease. W H O  
has developed comprehensive guidelines for the surveillance of 
STDs that can be accessed at the following Web site: http:// 
www.who.int/emc-documents/STIs/docs/STI%20Guidelines.html 
(Note: a synonymous term for STDs used by W H O  is sexually 
transmitted infections or STIs). The Centers for Disease Control 
and Prevention (CDC) has developed guidelines for evaluating 
surveillance systems that can be accessed at the following Web site: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5013a1.htm.
For more detail on designing and implementing reproductive health 
surveillance systems, and analysis of surveillance data, see the 
Reproductive Health Surveillance Module.
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W hat Are Some Issues in Surveillance o f RTIs?
Even good surveillance systems vary greatly in their accuracy 
and completeness, and many RTIs are asymptomatic or have non­
specific symptoms, making case diagnosis and reporting difficult. 
Self-treatment using medications from pharmacists and use of 
traditional remedies are common in many parts of the world. As a 
result, many infected women do not visit health clinics, and those 
who do seek care may be improperly diagnosed or not treated. The 
collection of data on RTIs is made more difficult because the highest 
prevalence o f RTIs is often found within socially marginalized or 
stigmatized groups, such as prostitutes and substance abusers, or 
groups that are relatively inaccessible to health care providers and 
researchers, such as adolescents (13). The social stigma associated 
with RTIs may deter women from attending STD clinics and result 
in women seeking care from alternative providers who may be less 
likely to report cases. Accordingly, not all cases are reported and the 
total number of new cases for many RTIs is often underestimated.
In addition, reliable data on the complications and sequelae of RTIs, 
such as pelvic inflammatory disease and ectopic pregnancy, are few, 
even though complications are the cause of much o f the burden of 
morbidity associated with RTIs.
Laboratory-Based Surveillance
The traditional approach to the diagnosis and treatment of RTIs is 
through laboratory diagnosis to determine the etiologic agent causing 
infection. Laboratory tests are used to confirm symptomatic infec­
tions, to detect asymptomatic infections, to perform epidemiologic 
surveillance, and to monitor disease sensitivity to antibiotic treatment 
(antibiotic resistance). Ideally, laboratory tests for specific RTIs 
should be simple to perform, sensitive and specific, rapid, inexpen­
sive, and should not require special equipment. Two important 
concepts in laboratory-based RTI surveillance are sensitivity and 
specificity (Appendix B). Sensitivity indicates how accurately a test can 
identify diseased persons and specificity indicates how accurately a 
test can identify those who are free of disease.
Although the use o f laboratory diagnostics is the preferred approach, 
it tends to be expensive in terms of tests, equipment, and laboratory 
maintenance and often results in delays in diagnosis and treatment. In 
reality, simple, affordable, and accurate diagnostic tests are not cur­
rently available for many RTIs. In many developing regions, it is 
usually not possible to detect the pathogen since most clinics lack the 
capacity, resources, training, or laboratory support to comprehen­
sively examine clients for RTIs (5).
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Is There an Alternative to Laboratory-Based 
Surveillance in Resource-Poor Settings?
In response to the limitations of laboratory-based surveillance in many 
parts of the world, W H O  developed a syndromic approach to RTI 
management. The syndromic approach to RTI management uses 
clinical algorithms based on STD syndromes (i.e., the pattern of 
patient symptoms and clinical signs) to determine antimicrobial 
therapy (23). Using this approach, groups o f symptoms and signs of 
infection are identified without laboratory tests and treatment is admin­
istered for all possible infections using drugs of proven local efficacy.
/ ----------------------------------------------------------------------------------------- \
Syndromic diagnosis is based on identifying consistent groups 
of symptoms and easily recognized signs, or syndromes, and 
providing treatment that will deal with the majority of organisms 
responsible for producing each syndrome.
Source: World Health Organization. Guidelines for the management o f  sexually 
transmitted infections. Geneva, Switzerland: World Health Organization; 2001 .
V___________________________________________________________________________________ /
The syndromic approach can be used with minimal economic re­
sources and is currently implemented in primary health centers in 
several parts of the world. The advantages o f this approach include 
treatment at first visit, expedited care, cost savings because expensive 
laboratory tests are not used, and increased client satisfaction (23). 
Providing treatment at the first visit reduces the risk o f losing patients 
and having no follow-up care, and this in turn reduces further trans­
mission and complications from untreated infections. The use of 
flowcharts in RTI management can help to standardize the diagnosis, 
treatment, referral, and reporting o f STDs, which allows for im­
proved surveillance and program management. However, the 
syndromic approach has many limitations that must be recognized, 
including the large number of asymptomatic infections, the lack of 
sensitivity and specificity for some diagnoses, and the variability in 
the performance of the decision models based on the clinical skills of 
the provider (23).
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A variety o f demographic, behavioral, and clinical factors can also be 
used to assess the likelihood that a woman is currently infected with 
an RTI or is at high risk of future infection (24). These factors can 
then be used to guide the syndromic management of infections in 
symptomatic patients (especially among women with vaginal dis­
charge) and to identify asymptomatic clients who might 
need further clinical examination or laboratory evaluation (25).
A review of several studies that evaluated the effectiveness of various 
syndromic management algorithms, including risk assessments, 
concluded that algorithms for urethral discharge and genital ulcer 
disease can be effective in detecting those infections, given their 
relatively high sensitivities and specificities (26). However, the 
sensitivities and specificities for the vaginal discharge algorithms 
varied considerably from one study to another and overall were not 
found to be effective in detecting vaginal infections, particularly 
among asymptomatic or low-risk women.
Issues in M onitoring Progress Toward the 
Reduction o f RTIs
Estimating the magnitude o f the morbidity associated with RTIs is a 
challenging task; nevertheless, determining the magnitude of the 
problem is essential so that progress toward the reduction of RTIs 
may be monitored. Self-reporting o f RTIs in women is unreliable 
because of nonrecognition of symptoms and the high rate of asymp­
tomatic infections (18). Sentinel surveillance and case reporting 
methods are highly sensitive to site selection, use or provision of 
services, health infrastructure, and provider compliance in reporting. 
The ability to diagnose certain infections may vary depending on 
medical technology available. As screening services improve, rates of 
RTIs may appear higher because o f better case detection. For these 
reasons, the validity, reliability, and representativeness o f estimates are 
widely variable and should be regarded with caution; nevertheless, 
surveillance should be considered an essential part o f monitoring 
RTIs to determine the need for public health action and to evaluate 
the effectiveness of RTI prevention and control programs.
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Ge n e r a l  Mo d e l  a s  Fr a m e w o r k  f o r  
St r a t e g ic  Pl a n n in g  f o r  Co n t r o l  a n d  
Pr e v e n t io n  o f  RTIs
Although strategies for RTI control programs vary between developed 
and developing countries and within countries, the two basic prin­
ciples that are common to all programs are 1) the prevention of the 
development of RTIs, their complications, and sequelae; and 2) the 
interruption and reduction of the transmission o f RTIs (3). Effective 
control programs encourage the avoidance of behaviors likely to result 
in disease acquisition and transmission and ensure optimal treatments 
for RTIs. In individuals, early and effective treatment of RTIs is 
considered an essential component of the control of RTIs and HIV.
At the population level, early and effective treatment prevents further 
transmission of RTIs and reduces HIV transmission (23). Identifying 
infected individuals, both symptomatic and asymptomatic, also 
plays an important role in control programs. Infected people can 
be detected through screening of those at high risk for RTI, through 
syndromic diagnosis and treatment, and by increasing the availability 
and rapidity o f treatment, thus improving partner tracking and 
notification. Occasionally, identification of individuals is bypassed 
with mass treatment to eradicate the pathogen in a core group 
identified as having a high prevalence of RTI.
/  \
General Principles for RTI Control
The main goals of RTI control are accomplished by the following steps:
1. Reducing exposure to infection by educating people at risk to reduce the 
number of sex partners and to avoid sexual intercourse with people who 
have a high probability of being infected.
2. Preventing infection by promoting the use of condoms or other prophylactic barriers.
3. Detecting and curing disease by implementing disease detection activities, 
providing adequate diagnostic and treatment facilities, and promoting 
health-seeking behavior.
4. Limiting complications and further transmission of infection by providing early 
and appropriate treatment for symptomatic and asymptomatic patients and 
their sex partners, and through counseling.
Adapted from: Meheus A, Schulz K, Cates W. Development o f  prevention and control programs for sexually
transmitted diseases in developing countries. In: Holmes KK, Mardh P, Sparling PF,Wiesner PJ, Cates W,
Lemon SM , et al., editors. Sexually transmitted disease. New York: McGraw-Hill; 1990. p. 1041-6.
V______________________________________________________________________________ /
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Most bacterial and parasitic genital infections are fully curable with 
antibiotics. Disease control strategies based on early diagnosis and 
treatment and health-seeking behaviors are important determinants 
of the incidence o f curable RTIs (27). However, not all curable RTIs 
can be controlled equally. This is especially true in developing coun­
tries, where the absence of resources necessary for diagnosis makes 
certain curable infections (e.g., gonorrheal or chlamydial infection) 
comparable to the incurable viral RTIs.
Although viral infections cannot currently be cured, their complica­
tions may be minimized. For this reason, health-seeking behaviors 
are still important in the epidemiology of these diseases. However, 
primary prevention remains the key intervention. Control strategies 
for viral RTIs largely depend on efforts at primary prevention through 
health education of the community and individualized counseling of 
infected carriers (27). For example, HIV can be transmitted from an 
infected woman to her fetus or newborn during pregnancy, during 
labor and delivery, and during the postpartum period (through 
breastfeeding). Perinatal transmission rates ranging from 13% to 
40% have been estimated, depending on the prevalence o f various 
factors that influence the likelihood of HIV transmission. For this 
reason, HIV counseling and testing for women of childbearing 
age offer important prevention opportunities for both uninfected 
(primary prevention) and infected (secondary prevention) women 
and their infants.
Comprehensive guidelines for the treatment of patients who have 
STDs were developed by CD C and can be accessed at: http://www. 
cdc.gov/std/treatment/TOC2002TG.htm.
Prevention o f RTIs
Although some RTIs are not curable, all are preventable. Generally 
speaking, primary prevention activities are designed to reduce the 
occurrence of disease before the pathogen has interacted with the 
host (28). Secondary prevention occurs after the pathogens have 
interacted with the host, and intends to reduce the progression of 
the disease.
Prevention o f RTIs is an important message for all people, including 
those at low risk. Primary prevention involves avoiding infection in 
the first place; the most effective way to prevent sexual transmission of 
RTIs is to avoid sexual intercourse with infected partners. Secondary 
prevention reduces the likelihood of complications and sequelae of 
RTIs. Prevention goals require that people adopt preventive behaviors 
(such as avoiding unprotected intercourse with infected partners) and
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General Guidelines for the Prevention of RTIs/STDs
The best way to prevent sexually transmitted diseases (STDs) and reproductive
tract infections (RTIs) is to not have sexual relations. However, if you do decide to
be sexually active, there are ways to reduce the risk of contracting an STD or RTI:
• Ask a new sex partner if he or she has an STD/RTI, has been exposed to one, 
or has any unexplained physical symptoms. Do not have sex if your partner has 
signs or symptoms, such as sores, rashes, or discharge from the genital area.
• Many common STDs/RTIs have no symptoms but can still be transmitted to 
a sexual partner. If your partner has had sexual relations with someone else 
recently, they may have an infection, even if there are no symptoms. Therefore, 
do not have sex if you think your partner may have been exposed to an STD/ 
RTI, even if they do not show any symptoms.
• Use a condom correctly and consistently during all types of sexual intercourse 
(oral, vaginal, and anal).
• Get regular checkups for STDs and RTIs (even if you show no symptoms), 
and be familiar with the common symptoms.
• Most bacterial infections are readily treated, and the earlier treatment is 
sought and sex partners are warned, the less likely the disease will do 
irreparable damage.
Source: CDC National Prevention Information Network (NPIN) Web site (www.cdcnpin.org/scripts/std/
index.asp).
that clinicians diagnose and treat existing infections effectively (7). 
Especially since the advent o f the AIDS epidemic, initiatives to 
market and encourage the use of condoms have been central to RTI 
control programs because condoms reduce acquisition and transmis­
sion of both RTIs and HIV infection (29).
How D o Strategies for the Control and 
Prevention o f Viral and Bacterial RTIs Differ?
There are significant differences in incidence, trends, distribution, 
and epidemiologic determinants between incurable, viral RTIs 
and curable, mostly bacterial RTIs. Health-seeking behaviors and 
disease control strategies based on early diagnosis and treatment are 
important determinants of the incidence o f the curable RTIs. The 
traditional interventions o f secondary prevention and management 
applied to bacterial RTIs will have a threefold effect: 1) to decrease 
transmission of bacterial RTIs within communities; 2) to reduce 
the reproductive sequelae o f those RTIs; and 3) to slow the HIV 
epidemic, particularly through controlling genital ulcers.
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Health-seeking behaviors are less effective in the epidemiology 
of incurable, viral RTIs. Mainly due to the increasing importance 
of incurable, viral RTIs, particularly HIV, strategies for primary 
prevention are receiving much higher priority today than in the 
past decade (28). The epidemiologic synergy between HIV and 
other RTIs is an important concept underlying RTI risk (7).
Strong evidence indicates that both ulcerative and nonulcerative 
RTIs significantly increase the risk of acquiring and subsequently 
transmitting HIV. Preexisting STDs, such as herpes simplex virus, 
syphilis, and chancroid, especially when associated with genital 
tract ulcers, increase women’s vulnerability to the transmission of 
HIV three to five times (30). Furthermore, because the impaired 
immune system caused by HIV disease leads to persistent ulcerative 
symptoms, the infections have a direct effect on each other. Infections 
characterized by vaginal or urethral discharge (e.g., gonorrhea and 
chlamydia) have also been associated with higher levels of HIV 
infection. Because these infections are more common than genital 
ulcers, they make up a larger proportion of HIV transmission. Pri­
mary prevention efforts to reduce risky sexual behavior will not only 
help reduce the risk of HIV, but will be beneficial in the prevention 
of all RTIs. RTI control activities reduce the likelihood of transmis­
sion to sex partners; thus prevention for individuals translates into 
prevention for the community (29).
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I m p l ic a t io n s  o f  R e s e a r c h  a n d  
U ses o f  C o l l e c t e d  D a t a
Surveillance systems and descriptive epidemiologic studies show the 
frequency distribution, and trends of disease within populations and 
are used to detect changes that may necessitate control measures or 
further research. Analytical studies provide measures of the strength 
of the association between particular characteristics, behaviors, 
exposures, or interventions, and the occurrence of disease.
How Are Surveillance Data Used?
Data from both surveillance systems and epidemiologic studies play 
an important role in informing the design, implementation, and 
evaluation of RTI treatment and prevention programs. These data 
may be used for setting public health priorities, planning, resource 
allocation, and identifying population subgroups and risky behaviors 
for targeted interventions (13).
Epidemiologic data are particularly important in settings with limited 
resources for establishing priorities and guiding decision making. In 
these settings, cost-effectiveness studies of RTI control programs are 
especially important as a means o f securing the necessary resources.
In all settings, epidemiologic data can provide useful information 
for diagnostic and therapeutic practice and indicate areas for further 
research. Epidemiologic studies can pave the way for the development 
of indicators and practical ways o f estimating the burden of RTIs at 
the local level; laboratory-based surveillance can provide information 
on antimicrobial susceptibilities of infectious agents (31). The chal­
lenge for those involved in surveillance or epidemiologic studies is to 
present their data in ways that will initiate effective control measures 
and to ensure that control programs are data-driven (13).
W ho Needs to Know the Results 
o f the Research, and Why?
Interpreting and communicating the results are the next steps in the 
process o f transforming the data into information for action. Good 
data play a crucial role in allowing health staff to modify and refine 
field operations and also in focusing the attention of policymakers 
on the burden of morbidity and mortality due to RTIs. Therefore, 
those who need to know the findings include those who are the 
source of the primary data (such as health care providers and labora­
tory personnel) as well as those who are involved in administrative, 
program planning, and decision-making activities.
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Results and recommendations serve to inform and motivate health 
personnel who are more likely to continue the challenging job of 
collecting information if they know that the information is being 
used and acted on. Feedback is important between the regional and 
national levels. For example, a need may be identified for training or 
resources at the local level that can only be obtained from the regional 
level. This communication may be facilitated through periodic 
meetings at the regional and national levels.
How Can We Tell W hether an RTI Control 
Program Is Achieving Its Goals?
To assess the degree to which a control program is achieving its goals 
and targets, a system for monitoring and evaluation must be feasible. 
Regular review of RTI control and prevention programs allows health 
staff to modify and refine health actions taking place in the field. 
Evaluation is an important step in promoting the best use o f public 
health resources and should include recommendations for improving 
quality and efficiency. Most importantly, an evaluation should assess 
whether the program is serving a useful public health function and is 
meeting its overall objective o f reducing the burden of morbidity and 
mortality due to RTIs.
Evaluation generally involves the definition of indicators to track 
the program’s progress toward explicit objectives. Once the objectives 
of a program have been defined, indicators (such as the long-term 
outcome indicators discussed earlier) are used as markers of progress 
toward those objectives. An indicator can be thought o f as a measure­
ment that provides information regarding a health outcome com­
pared with a standard or desired level of achievement. The calculation 
of these indicators can be repeated over time as a measure of progress. 
For example, repeated measurement of an indicator, such as the pre­
valence o f RTIs in a defined target population, is integral in the eval­
uation of the effectiveness and impact of a program aimed at improv­
ing reproductive health or achieving specific targets (e.g., a reduction 
in maternal morbidity).
In summary, the goal of evaluation is to:
• Select appropriate interventions that reflect local needs.
• Build on lessons learned and programs that have worked in 
other countries.
• Implement interventions according to current best practices.
• M onitor progress.
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Evaluation can be used to guide the planning of effective RTI control 
and prevention programs, improve existing programs, and demon­
strate the results o f resource investments and interventions such as 
large-scale integration of services.
Reproductive tract infections continue to be a major and growing 
public health issue in many parts of the world and are particularly 
widespread in resource-poor settings. W ithout early diagnosis and 
appropriate therapy, complications of RTIs severely compromise 
women’s health, fertility, and productivity; infant health and survival; 
and the effectiveness of family planning programs. Interventions that 
truly decrease the burden o f RTIs will involve the coordination of 
efforts among several interrelated health initiatives and will include 
changes in the outlook, knowledge, skills, and resources of all levels 
of the health care system.
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Re s o u r c e s
Selected RTI/STD /H IV Information Web sites (Adapted from: 
Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, et al. 
Contraceptive technology. New York: Ardent Media; 1998. p. 273-4.)








Centers for Disease Control and Prevention:
http://www.cdc.gov/nchstp/dstd/dstdp.html
CDC National Prevention Information Network:
http://www.cdcnpin.org








National Center for HIV, STD & TB Prevention:
http://www.cdc.gov/nchstp/od/nchstp.html
National Institute of Allergy and Infectious Diseases (NIAID):
http://www.niaid.nih.gov
Population Services International (PSI):
http://www.psi.org




Re p r o d u c t i v e  He a l t h  Ep id e m io l o g y
Se r ie s — Mo d u l e  3
Case St u d y  I
Ep id e m io l o g y  o f  STDs 
Ou t b r e a k  In v e st ig a t io n
• •

Module 3: Reproductive Tract Infections Case Studies
Ca s e  St u d y  I: Ep i d e m i o l o g y  o f  STDs : 
Ou t b r e a k  In v e s t i g a t i o n
Part I:
The investigation of an ongoing outbreak requires quick action and a 
systematic approach to help ensure that the investigation proceeds 
rapidly. The sequence of an outbreak investigation is outlined below.
Steps o f  an Outbreak Investigation
1. Prepare for field work
2. Establish the existence of an outbreak
3. Verify the diagnosis
4. Define and identify cases
a. Establish a case definition
b. Identify and count cases
5. Perform descriptive epidemiology
6. Develop hypotheses
7. Evaluate hypotheses
8. Reconsider/refine hypotheses and execute further studies as 
necessary
a. Additional epidemiologic studies
b. O ther types of studies (e.g., laboratory, environmental)
9. Implement control and prevention measures
10. Communicate findings
Source: CD C. Principles of epidemiology: an introduction to applied epidemiology 
and biostatistics. Atlanta (GA): Centers for Disease Control and Prevention; 1992.
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Q1: The following table shows early syphilis (primary and secondary) 
rates for 1993-1997, for the city of Baltimore, Maryland, United 
States.
1993 1994 1995 1996 1997
U.S. to ta l .......................................... ............................. 10.3 7.9 6.3 4.3 3.2
M aryland  (sta te )............................. ...............................  7.2 6.5 11.0 14.4 17.6
B altim ore (c ity ).............................. .............................20.1 27.3 60.3 81.9 99.1
a) Divide into three small groups and let each group draw a line 
graph of the epidemic curve: one for the United States, one for 
Maryland, and one for Baltimore.
b) As a whole group, compare the epidemic curves. Would you 
say that, compared with the entire United States, there was a 
syphilis epidemic in Maryland? In Baltimore?
c) How much higher were syphilis rates in Baltimore than in the 
entire United States in 1993?
d) How much higher were syphilis rates in Baltimore than in the 
entire United States in 1997?
e) Assume that you are a health officer working in Baltimore.
You have collected additional information on congenital 
syphilis and confirmed that since 1995 there has been a 
marked increase in congenital syphilis in Baltimore. You have 
information that confirms the epidemic. W hat additional steps 
will you take to investigate this outbreak?
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Part II:
Q2: Investigators have decided to ask two research questions:
• Has there been an increase in congenital syphilis in 
Baltimore during the 15-month study period?
• W hat factors are associated with the increase?
a) What type of study is needed to answer each of these questions—  
descriptive or analytic?
b) During the study period, 146 women were reported as having 
reactive syphilis serologies during pregnancy. The reporting 
forms for each of these women were reviewed by the study 
team. O f these 146 women, 56 were determined to have no 
active syphilis during pregnancy due to prior treatment, false 
positive serologies, or postpartum infection. W hat was the 
total number of women with active syphilis during pregnancy?
c) W hat two steps in the outbreak investigation have just been 
completed?
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d) The investigators decided to conduct a case-control study to 
compare women with inadequately treated syphilis during 
pregnancy with those who were adequately treated for syphilis 
during pregnancy. Adequate therapy is defined as a stage­
appropriate penicillin regimen started at least 30 days before 
delivery. The definition of inadequate therapy, then, includes 
no treatment, treatment started within 30 days of delivery, or 
treatment with no appropriate serologic response. W hich of 
the pregnant women would be the most appropriate cases in 
this investigation and which would be the most appropriate 
controls?
e) The investigators found that 28 women had adequately treated 
syphilis and 62 had inadequately treated syphilis. What 
percentage o f pregnant women with syphilis had adequately 
treated syphilis and what percentage had inadequately treated 
syphilis?
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Part III: Risk Factors
Q3: The following table summarizes some o f the findings from the 
case control study:
Cases Controls
M other’s toxicology screen at delivery
Cocaine positive............................................................................
Opiate positive*............................................................................




T im ing o f  syphilis diagnosis
Third trim ester*............................................................................ ......................................  43 (74%) 8 (29%)
H ad  any syphilis e d u c a tio n .......................................................... .........................................6 (10%) 5 (18%)
U nw anted pregnancy* .................................................................... ......................................  23 (37%) 4 (14%)
* P < .05
a) W hich risk factors were statistically significant?
b) After noting that late diagnosis was a significant risk factor for 
congenital syphilis, the investigators decided to examine the 
cases in further detail. They found that in 34 o f the cases, 
women either had no prenatal care or initiated prenatal care 
after 28 weeks. W hat percentage of the cases were in this 
category?
c) The significant findings have implications for the importance 
o f horizontal collaboration between STD and reproductive 
health providers. W hat are these implications?
The majority of these 34 women had contact with other providers 
(were in jail or had contact with social workers) who could have 
helped refer them into prenatal care at an earlier date.
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Part IV: Multivariate Analysis o f Factors 
Associated W ith Congenital Syphilis
Q4: In further analyses, the investigators used only birth certificate 
data and compared two groups: 1) birth certificate data for the 
38 black infants with congenital syphilis who were born in 
Baltimore in 1996 and 2) birth certificate data for the 5,966 
black infants without congenital syphilis who were born in 1996 
in Baltimore. They used logistic regression to adjust each risk 
factor for other risk factors in the statistical model. These results 
are shown below:
Factor Adjusted Odds Ratio (95% Confidence Interval)
Prenata l care
Started first trim ester..................................................................................................................................... 0 (referent)
Started second trim ester.............................................................................................................................2.7 (0.9-8.0)
Started third trim ester.........................................................................................................................  13.1 (4.2-40.7)
N o n e .......................................................................................................................................................  12.0 (3.6-39.7))
Father’s nam e m iss in g .................................................................................................................................7.9 (3.1-19.8)
G ravidity  > 4 ....................................................................................................................................................2.7 (1.1—6.8)
a) W hich o f  the risk factors are statistically significant?
b) How would you interpret the findings regarding prenatal care?
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Part V: Implement Control Measures
At the start of this epidemic, Maryland state law required a first and 
third trimester syphilis test for pregnant women. Since there was no 
specification regarding timing of the third trimester test, many of these 
were performed at delivery—too late to prevent congenital syphilis.
Q5: Among pregnant women who entered prenatal care by 28 weeks, 
syphilis screening at 28 weeks could have prevented 18 cases of 
syphilis. W hat proportion of the total cases could be prevented 
by this intervention?
Q6: W hat recommendations should the agencies conducting this 
investigation make to legislators regarding timing of the third 
trimester syphilis test?
Note: The legislation for the state of Maryland was changed in 
January 1998 as a consequence o f this investigation and now requires 
that the second syphilis test be conducted at 28 weeks o f gestation or 
the first visit thereafter.
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An s w e r s
Part I:
Q1:
a) (Line graphs o f epidemic curves)
b) There appears to be an epidemic in Baltimore, but not in the 
entire state of Maryland.
c) Twice
d) About 33 times higher
e) Additional steps to investigate this outbreak:
• Verify diagnosis
• Count cases
• Describe the epidemic
• Test hypotheses
• Implement control measures
Part II:
Q2:
a) A descriptive study is needed to answer the first question; an 
analytic study is needed to answer the second question.
b) 90
c) Diagnoses have been verified and cases have been counted.
d) The most appropriate cases would be pregnant women with 
inadequately treated syphilis and the most appropriate controls 
would be women with adequately treated syphilis.
e) Percentage of pregnant women with adequate treatment =
31% (28/90)
Percentage o f pregnant women with inadequate treatment = 
69% (62/90)
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Part III: Risk Factors
Q3:
a) Significant findings:
• Cases were significantly more likely than controls to have a 
toxicology screening that was opiate-positive (43% versus 11%).
• Cases were significantly more likely than controls to have 
syphilis diagnosed during the third trimester (74% versus 29%).
• Cases were significantly more likely than controls to report 
that their pregnancy was unwanted (37% versus 14%).
b) 55% (34/62)
c) The need for close collaboration between STD clinicians and 
reproductive health clinicians is evident. Although the STD 
clinicians are the experts in the diagnosis and treatment o f  
syphilis, reproductive health clinicians are the first group to see 
pregnant women for prenatal care, and the reproductive health 
clinicians are the group that could decrease unwanted pregnancy 
(thereby preventing congenital syphilis) by making modern 
family planning methods available.
Part IV: Multivariate Analysis o f Factors 
Associated W ith Congenital Syphilis
Q4:
a) Significant findings from birth certificate data:
• Starting prenatal care in the third trimester, or having no 
prenatal care
• Father’s name missing
• Gravidity o f 4 or more
• Out-of-hospital delivery
b) Two risk factors (no prenatal care and starting prenatal care 
in third trimester) have similar strength o f association with 
congenital syphilis. It appears that starting prenatal care in the 
third trimester may be too late for adequately diagnosing and 
treating syphilis prior to delivery.
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Part V: Implement Control Measures
Q5: Proportion of the total cases preventable by intervention = 
18/62 «  29%.
Q6: The syphilis test should be conducted at 28 weeks o f gestation, 
or at the first health care visit thereafter.
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Ca s e  St u d y  II: Ep i d e m i o l o g y  o f  STDs : 
Qu e s t i o n n a i r e  Ex e r c i s e
Your group is designing a study to evaluate the risk factors for syphilis
in women under the age o f 25 years who attend women’s consultation
clinics or dermatovenereology clinics. The following are the sexual
behaviors you want to measure:
• Sexual activity
• Consistent condom use with regular partners
• Consistent condom use with casual partners
• Unprotected intercourse with regular partners
• Unprotected intercourse with casual partners
• Number of sex partners
• Exchanging sex for money
• Exchanging sex for drugs
• Use of intravenous drugs
1. Each group member should take several minutes to develop a 
question to measure one of the previous behaviors (5 minutes).
2. Each member of the workgroup should read his or her question to 
the group (5 minutes).
3. Group members can then work together to revise/improve each 
others’ questions (10 minutes).
4. Attached are some sexual behavior questions that have been used 
previously in a variety of national surveys. (Although a discussion 
of questionnaire design is beyond the scope of this case study, it 
may help you to be aware that the SKIP pattern or other directions 
in CAPS and the numerical codes at the end o f each response are 
used to facilitate and standardize interviewing and data entry.) 
Discuss how the questions should be modified to be culturally 
appropriate for use with patients in a dermatovenereology clinic 
or a women’s consultation clinic.
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1. During the past 12 months, have you had sex? By “sex” we mean 
only oral, vaginal, or anal sex.
Yes.................................................................................... 1
N o ....................................................................................2 SKIP to END
Refused............................................................................ 9
2. During the past 12 months, with how many different people have 
you had sex?
N um ber................................................................... ..........
Don’t know/Not su re .............................................  777
Refused.....................................................................  999
3. During the past 12 months, have you had sex with only males, only 
females, or with both males and females. PLEASE MARK ONE 
BOX FOR TH E BEST ANSWER
Only males.......................................................................1
Only females................................................................... 2
Both males and females.................................................3
Refused ............................................................................ 9
4. I’m going to read you a list. W hen I’m done, please tell me if any of 
the situations apply to you. You don’t need to tell me which one.
• You have used intravenous drugs in the past year.
• You have been treated for a sexually transmitted disease 
or venereal disease in the past year.
• You tested positive for having HIV, the virus that causes AIDS.
• You had anal sex without a condom in the past year.
Do any of these situations apply to you?
Yes ....................................................................................  1
No .................................................................................... 2
Don’t know/Not su re ................................................... 7
Refused........................................................................... 9
[Note: The above question may be too nonspecific for use in 
high-risk populations. However, if direct comparison with a general 
population survey is desired, this question should probably be 
included and be followed or be replaced by the following more 
specific questions.]
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5. During the past 12 months, have you used a needle to inject a 
drug that was not prescribed for you, or that you took only for the 
experience it caused?
Yes ...................................................................................  1
N o .................................................................................... 2
Refused ...........................................................................  9
6. During the past 12 months, has a doctor or nurse told you that 
you had a sexually transmitted disease, for example, herpes, 
gonorrhea, chlamydia, or genital warts?
Yes ...................................................................................  1
N o ....................................................................................2
Don’t know/Not su re ................................................... 7
Refused ...........................................................................  9
7. Have you ever been told that you were infected with the AIDS 
virus (HIV)?
Yes ...................................................................................  1
N o ....................................................................................2
Don’t know/Not sure ...................................................  7
Refused ...........................................................................  9
8. During the past 12 months, have you given drugs for sex or 
received drugs for sex? Remember to include only oral, vaginal, 
or anal sex.
Yes ...................................................................................  1
N o ....................................................................................2
Refused ...........................................................................  9
9. During the past 12 months, have you given money for sex
or received money for sex? Remember to include only oral, vagi­
nal, or anal sex.
Yes ...................................................................................  1
N o ....................................................................................2
Refused........................................................................... 9
[Note: Some surveys have combined questions 8 and 9, for 
example: In the past 12 months, have you given or taken money 
or drugs in exchange for sex?]
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SAY: Now, I would like you to think back to the last time you 
had sex. Remember that by “sex” we mean only oral, vaginal,
or anal sex.
10. The last time you had sex, was a condom used?
Yes................................................................................... 1
N o ...................................................................................2 SKIP TO
Question 13
Don’t know/Not su re .................................................. 7
Refused...........................................................................9




No ........................................................................  2
Don’t know .......................................................... 7
Did not have oral sex .......................................... 8
Refused ................................................................  9
11b. Vaginal sex
Yes........................................................................ 1
No ........................................................................  2
Don’t know .......................................................... 7
Did not have vaginal sex .................................... 8
Refused ................................................................  9
11c. Anal sex
Yes........................................................................ 1
No ........................................................................  2
Don’t know .......................................................... 7
Did not have anal sex.......................................... 8
Refused ................................................................  9
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12. Was the condom used...
To prevent pregnancy.................................................. 1
To prevent diseases like syphilis, gonorrhea, 
and AIDS ....................................................................  2
For both o f these reasons............................................3
For some other reason: Specify_________________ 4
Don’t know/Not sure ................................................. 7
Refused ......................................................................... 9
SAY: Now I’m going to ask you some questions about the person 
you last had sex with.




14. How long have you been having sex with this person?
Thirty days or less.......................................................  1
More than 30 days, but less than 6 m onths............2
Six months or more ...................................................  3
Refused ......................................................................... 9
15. Has this person ever injected (shot) drugs?
Yes ..................................................................................  1
N o ..................................................................................2
Don’t know/Not su re ..................................................7
Refused..........................................................................9
16. Has this person ever had a sexually transmitted disease, for 
example, herpes, gonorrhea, chlamydia, or genital warts?
Yes ..................................................................................  1
N o ..................................................................................2
Don’t know/Not su re ..................................................7
Refused..........................................................................9
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17. Does this person have the AIDS virus (HIV)?
Yes................................................................................... 1
No ..................................................................................  2
Don’t know/Not su re .................................................. 7
Refused...........................................................................9
18. During the past 12 months, has this person given drugs for sex or 
received drugs for sex?
Yes................................................................................... 1
No ..................................................................................  2
Don’t know/Not su re .................................................. 7
Refused...........................................................................9
19. During the past 12 months, has this person given money for sex 
or received money for sex?
Yes................................................................................... 1
No ..................................................................................  2
Don’t know/Not su re .................................................. 7
Refused...........................................................................9
20. The last time you had sex with this person, had you been drinking 
alcohol before you had sex?
Yes................................................................................... 1
No ..................................................................................  2
Don’t know/Not su re .................................................. 7
Refused...........................................................................9
21. The last time you had sex with this person, had you been using 
drugs like cocaine, heroin, crack, speed/crank, or marijuana before 
you had sex?
Yes................................................................................... 1
No ..................................................................................  2
Don’t know/Not su re .................................................. 7
Refused...........................................................................9
[Adapted from previous similar questions: “During the past 
12 months, how often had you been using drugs like cocaine, 
heroin, crack, speed/crank, or marijuana before you had sex?” 
and “This most recent time you had sex, did either you or your 
partner use drugs to get high or intoxicated before or during sex?”]
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22. The last time you had sex, was it with someone you are/were in 
an ongoing relationship with or who you consider(ed) to be your 
main sexual partner?
Yes....................................................................................1
N o ................................................................................... 2 SKIP to END
Refused........................................................................... 9
[The following set of questions are the same as questions 10-22, 
but they are asked for the last time a person had sex with someone 
other than their main sexual partner. Since there is no known 
precedent for this method, its benefits and disadvantages should 
be considered prior to use.]
23. In the past 12 months, have you had sex with someone other than 
your main sexual partner?
Yes................................................................................... 1
N o ...................................................................................2 SKIP to END
Refused...........................................................................9 SKIP to END
SAY: The next couple o f questions are about the last time you had 
sex with this other partner. Remember, by “sex” we mean oral, 
vaginal, or anal sex.
24. The last time you had sex with this person, was a condom used?
Yes................................................................................... 1
N o ...................................................................................2 SKIP to
Question 27
Don’t know/Not su re .................................................. 7
Refused...........................................................................9
25. The last time you had sex with this person, was a condom used for:
25 a. Oral sex
Yes.........................................................................  1
No ........................................................................  2
Don’t know .......................................................... 7
Did not have oral sex ........................................  8





Don’t know .......................................................... 7
Did not have vaginal sex .................................. 8
Refused ................................................................ 9
25 c. Anal sex
Yes........................................................................ 1
No ........................................................................ 2
Don’t know .......................................................... 7
Did not have anal sex.........................................8
Refused ................................................................ 9
26. Was the condom used...
To prevent pregnancy................................................. 1
To prevent diseases like syphilis, gonorrhea,
and AIDS .............................................................2
For both o f these reasons............................................ 3
For some other reason: Specify_________________ 4
Don’t know/Not sure ................................................. 7
Refused .........................................................................  9
SAY: Now I’m going to ask you some questions about this person.
27. Is/was this person a man or a woman?
Man ............................................................................... 1
W om an.......................................................................... 2
Refused .........................................................................  9
28. How long have you been having sex with this person?
Thirty days or less.........................................................1
More than 30 days, but less than 6 m onths.............2
Six months or m o re .....................................................3
Refused...........................................................................9
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29. Has this person ever injected drugs?
Yes..................................................................................1
No ..................................................................................  2
Don’t know/Not su re ................................................. 7
Refused..........................................................................9
30. Has this person ever had a sexually transmitted disease, for 
example, herpes, gonorrhea, chlamydia, or genital warts?
Yes................................................................................. 1
No ................................................................................. 2
Don’t know/Not su re ................................................. 7
Refused..........................................................................9
31. Does this person have the AIDS virus (HIV)?
Yes..................................................................................1
No ..................................................................................  2
Don’t know/Not su re ................................................. 7
Refused..........................................................................9
32. During the past 12 months, has this person given drugs for sex or 
received drugs for sex?
Yes................................................................................. 1
No ................................................................................. 2
Don’t know/Not su re ................................................. 7
Refused..........................................................................9
33. During the past 12 months, has this person given money for sex 
or received money for sex?
Yes..................................................................................1
No ..................................................................................  2
Don’t know/Not su re ................................................. 7
Refused..........................................................................9
_________________________Reproductive Health Epidemiology Series
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34. The last time you had sex with this person, had you been drinking 
alcohol before you had sex?
Yes..............................
N o ...............................






35. The last time you had sex with this person, had you been using 
drugs like cocaine, heroin, crack, speed/crank, or marijuana 
before you had sex?
As part o f an initiative to address behavioral surveillance for 
HIV/STD prevention, the Behavioral Surveillance Workgroup 
at the National Center for HIV, STD, and TB Prevention, CDC 
has drafted a core set of sexual behavior questions. This module 
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Ap p e n d ix  A. Ov e r v i e w  o f  Co m m o n  RTIs  a n d  STDs
A dapted from: C D C . Family planning methods and practice: Africa. 2nd ed. A tlanta (GA): C D C; 1999.
Disease Symptoms Diagnosis Treatment Patient
(Pathogen) Instructions
Bacterial Excessive or foul- Presumptive diagnosis: Recommended regimens: Understand how
vaginosis, smelling vaginal Typical symptoms of Metronidazole 400—500 mg to take or use
Anaerobic discharge. Other signs vulvovaginitis, elevated PO  twice a day for 7 days any prescribed
vaginosis include erythema, vaginal pH  (> 4.7), and OR  Metronidazole 2 g PO medications.
irritation, and intense presence of clue cells in once. Avoid drinking
Clinical syndrome itching of the external saline wet m ount or gram alcohol until
of anaerobic genitalia. Frequently stain of vaginal discharge. Metronidazole is contraindi- 24 hours after
vaginal bacteria assumed to be normal Diagnosis enhanced with cated during the first trimester completing
(e.g., Gardnerella discharge by develop- fishy odor of vaginal of pregnancy but may be used, metronidazole
vaginalis, Myco­ ing world women. discharge after addition if necessary, during the second medication.
plasma hominis, of 1—2 drops of 10% and third trimesters. Data on
and other potassium hydroxide alternative regimens are very
anaerobes) (KOH). Cultures are limited. Clindamycin 300 mg
overgrowing not useful. Only PO  twice a day for 7 days has
normal lactobacilli symptomatic women 
need to be treated. Male 
sex partners do not.
been used successfully and this 
regimen would be safe in 
pregnancy.
Chancroid Frequently asymp- Presumptive diagnosis: Recommended regimen: Obtain HIV
tomatic in women. Clinical presentation Erythromycin 500 mg PO testing because
(Haemophilus Symptoms appear consistent with chan- 3 times a day for 7 days. genital ulcers are
ducreyi) 3—10 days after croid, a unilateral bubo, associated with
infection. Typically a or both. Diagnosis by Alternative regimens: HIV. Refer sex
single (sometimes exclusion of other STDs Ciprofloxacin 500 mg PO partners for
multiple) painful, causing genital ulcers: once OR  Ceftriaxone 250 mg treatment.
irregularly-shaped negative darkfield IM  once O R  Spectinomycin Carefully clean
genital ulcer. Ulcer is microscopy or serologic 2 g IM once OR Trimethoprim ulcerative lesion(s)
soft, and its base may testing (syphilis) AN D (80 mg)/ Sulphamethoxazole 3 times a day.
be covered with grey inconsistent clinical (400 mg) 2 tablets twice a day Use condoms to
purulent exudate. presentation of ulcer(s) for 7 days. prevent future
Ulcer usually on the or negative culture infections.
penis or at entrance to (genital herpes). The latter regimen has been
vagina or anus. Ulcers shown to be less effective in
usually disappear Definitive diagnosis: some parts of Africa and
without treatment in Identification of H. should only be used in areas
about 1 month. ducreyi on special culture where in vitro resistance rates
Painful inguinal media. are low and monitored
adenopathy (tender­ regularly. Due to widespread
ness of groin) in 50% resistance, tetracycline and
of cases. penicillins should not be used.
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Chlamydia Sexually transmitted 
infections caused by 
(Chlamydia C. trachomatis. 
trachomatis) Symptoms usually 
appear 7—21 days 
after infection and 
include purulent 
cervical discharge or 




spotting after sexual 
intercourse, pain on 
urination, and lower 
abdominal pain.
Can lead to PID, 
ectopic pregnancy, 
and infertility in 
women and chlamy­
dial ophthalmia 
and pneumonia in 
newborns. Often, 





Diagnosis usually by exclusion, 
in the absence of culturing 
techniques. In symptomatic 
women, presence of yellow 
mucopurulent endocervical 
exudate. In asymptomatic 
women, presence of S10 PM N 
leukocytes per x 1,000 field on 
Gram’s stain of endocervical 
mucus. In symptomatic men 
(with negative gonorrhea tests), 
white blood cells on Gram’s 
stain of urethral discharge OR 
sexual exposure to an NGU- 
causing agent. In asymptomatic 
men (with negative gonorrhea 
tests), S4 PM N  leukocytes per x 
1,000 field on intraurethral 
smear.
Definitive diagnosis:
Diagnosis by observed growth 
on cycloheximide-treated 
McCoy cells. Fluorescent 
monoclonal antibody stains or 
enzyme immunoassay tests may 
be available. Future use of DNA 
amplification techniques may 
increase sensitivity.
Recommended regimens: Sex partners
Doxycycline 100 mg PO twice must be treated.
a day for 7 days OR Tetracycline Use condoms to
500 mg PO 4 times a day for prevent future
7 days. infections.
Tetracyclines are contraindicated 
during pregnancy.
Alternative regimens (for patients in 
whom Tetracyclines are contraindicated 
or not tolerated):
Erythromycin 500 mg PO 4 times a 
day for 7 days OR, if Erythromycin 
is not tolerated, Sulfisoxazole 
500 mg PO 4 times daily for 
10 days. Equivalent doses of 
other sulphonamides may be 
used. Azythromycin 1 g PO once 
is effective treatment for chlamydia 
urethritis, but because its efficacy has 
not been proven in nongonococcal 
urethritis, it only should be used 
where a chlamydial etiology has 
been proven. This regimen is also 
expensive. (Gonorrhea resistance has 
been documented. This resistance, 
plus expense and side effects from 
a 2 g PO dose, make this regimen 







Appear as single or 





penis, anus, urethra, 
or perineum. In 
women, growths 
may occur on 
vaginal or cervical 
walls and not be 
noticed. Symptoms 
appear from one to 
several months after 
infection. HPV 
cannot be cured, 
even if warts 
disappear. Can 
cause cervical 
and other genital 
cancers in adults.
Presumptive diagnosis:
By typical clinical presentation 
on the external genitalia or 
of koilocytosis on Pap smear 
specimens. Colposcopy may 
aid in diagnosis of certain 
cervical lesions. Exclude 
possibility of condyloma 
lata (flat, moist lesions) with 
darkfield microscopy or 
serologic tests for syphilis.
Definitive diagnosis:
By biopsy, but usually un­
necessary. Very atypical lesions, 
where neoplasia is a consider­
ation, should be biopsied 
before therapy. Some warts 
in the anogenital area are 
associated with genital 
dysplasia or carcinoma.
A Pap smear of cervical 
lesions shows typical 
cytologic changes.
Regimens for external genital, 
perianal, vaginal warts:
(Physical) Cryotherapy with 
liquid nitrogen, solid carbon 
dioxide, or cryoprobe OR electro­
surgery OR surgical removal.
(Chemical) Podophyllin, 10%— 
25% in compound tincture of 
benzoin should be applied to 
warts, avoiding normal tissue.
Wash off warts thoroughly 1-4 
hours after podophyllin appli­
cation. Podophyllin should not 
be used for anal, urethral, oral, or 
cervical warts, and is contraindi­
cated during pregnancy and 
lactation. OR Trichloroacetic 
acid (80%-90%) applied to 
warts weekly.
Note: Treatment of cervical warts 
should not start until a satisfactory 
cervical smear is obtained. Manage­
ment should be carried out in 
consultation with an expert.
Sex partners do 
not need to be 
examined, as 


























appear 1—14 days 
after infection. 
Symptoms in men 




yellow or white 
purulent urethral 
discharge. Up to 
25% of infected 
men may be 
asymptomatic.
Often asymptomatic 




pain on urination, 
spotting after sexual 
intercourse, lower 
abdominal pain, and 
abnormal or painful 
menses. Infection 
can cause PID and 
sterility in women; 
urethritis, epid­
idymitis, and 






of typical gram-negative 
intracellular diplococci on 
smear of urethral exudate 
(men) or endocervical material 
(women) OR growth on 
selective medium demonstrat­
ing typical colonial morphol­
ogy, positive oxidase reaction, 
and typical Gram-stain 
morphology.
Definitive diagnosis:
Growth on selective medium 
demonstrating typical colonial 
morphology, positive oxidase 
reaction, and typical Gram- 
stain morphology, and 





Ceftriaxone 125 or 250 mg IM 
once OR Cefixime 400 mg PO 
once OR Spectinomycin 2 g IM 
once OR Ofloxacin 400 mg PO 
once OR Ciprofloxacin 500 mg 
PO once (contraindicated in 
pregnancy); however, gonorrhea 
resistance to Ciprofloxacin has 
been documented.
Alternative regimens:
Kanamycin 2 g IM once OR 
Trimethoprim (80 mg)/ 
Sulphamethoxazole (400 mg),
10 tablets PO once daily for 
3 days.
Kanamycin and Trimethoprim/ 
sulphamethoxazole should only 
be used in regions where 
N. gonorrhoeae are susceptible 
and susceptibility is monitored 
at regular intervals. Second-line 
treatment with recommended 
drugs should be available.
PLUS concurrent antichlamydial 
therapy such as Doxycycline 












to take any 
prescribed oral 
medications. 










8—80 days after 
infection. Single or 
multiple nodules 
appear below the 
skin at the site of 
inoculation. 
Nodules break 
through to form 
granulomatous 
ulcers that are 
painless, bleed on 
contact, and enlarge 
slowly. In men, 
ulcers appear on 
glans and prepuce 




Typical clinical presentation 
is sufficient. Resolution of 
lesions after antibiotic therapy 
supports diagnosis.
Definitive diagnosis: 
Microscopic exam of scrapings 
of biopsy specimens from the 
ulcer margin reveals typical 
Donovan bodies. Tissue 
culture not feasible.
regimen: 
Trimethoprim (80 mg)/ 
Sulphamethoxazole (400 mg),
2 tablets twice a day for a 
minimum o f l4  days and 
until lesions have completely 
re-epithelialized.
Alternative regimens:
Doxycycline 100 mg PO twice 
a day for 7 days OR 
Tetracycline 500 mg PO 4 times 
a day.
Understand how 
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Most HBV infections 
are clinically inappar­
ent. W hen present, 
symptoms usually 
develop 1—9 months 








dark urine, jaundice, 









By typical clinical 
symptoms and exposure 
to a patient with 
presumed or definitive 
HBV infection.
Definitive diagnosis: 
Serodiagnosis of HBV 
infection.
No known cure. HBV is the 
only STD that has a vaccine. 
Vaccination of all newborn 
infants and adolescents is 
recommended. People with 
a recent STD and those with 
more than one sex partner in 
the previous 6 months also 
should receive HBV vaccine.
People at risk for 
sexual transmis­
sion of HBV are 
also at risk for 
HIV and other 
STDs. Condoms 
should be used 









to HBV if 
administered 




virus (types 1 & 2)]
HSV-2 is more 
common in genital 
disease. Single or 
multiple small vesicles, 
usually pruritic, on 
the genitalia. Vesicles 
spontaneously rupture 
to form shallow ulcers 
that may be very 
painful. Other 
symptoms include 
pain on intercourse, 
pain on urination, 
discharge, fever, and 
malaise. Initial 
symptoms appear 1­
26 days after infec­
tion. First clinical 
occurrence is called 
first episode infection. 
Subsequent occur­
rences are usually 
milder and called 
recurrent episodes. 
HSV can be trans­
mitted to newborns 
during vaginal 
delivery and cause 
neonatal herpes. Risk 
of transmission is 
highest with primary 
infection.
Usually by clinical 
judgment. Likely when 
typical genital lesions are 
present or a pattern of 
recurrence has developed. 
Further supported by 
direct identification of 
multinucleated giant cells 
with intranuclear 
inclusions in a clinical 
specimen prepared by 
Papanicolaou or other 
serological techniques.
HSV tissue culture 
demonstrates the 
characteristic cytopath- 
ogenic effect following 
inoculation of a speci­
men from the cervix, 
urethra, or base of a 
genital lesion.
No known cure. Symptoms 
can be modified with Acyclovir 
treatment as soon as possible 
following onset of symptoms. 
Topical therapy with acyclovir 
produces only minimal 
shortening of the duration 
of symptomatic episodes and 
is not recommended.
' regimens:
First clinical episode: 
Acyclovir 200 mg PO 5 
times a day for 5 days. 
(Treatment can be expected 
to reduce formation of new 
lesions, duration of pain, time 
to healing, and viral shedding; 
however, treatment will not 
influence the natural history 
of recurrent disease.)
Recurrences:
Acyclovir 200 mg PO 
5 times a day for 5 days. 
Suppression of recurrent 
outbreaks (> 6 per year): 
Acyclovir 200 mg 3 times 
a day PO continuously.
Keep involved 
area clean and 
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(types L l, L2,
& U )]
Genital lesion is a 
small, painless vesicle 
or nonindurated ulcer 
(often unnoticed). 
Inguinal adenopathy 
(buboes) follows 1-4 
weeks after. Women 
may be asymptomatic, 
although some 
experience lower 
back pain and 
inguinal buboes. 
Symptoms appear 
after 3-12 days for 
genital lesion and after 
10-30 days for 
inguinal bubo. LGV 






clinically and should 
be differentiated from 
chancroid. A titer of 
1:64 on the LGV 
complement fixation 
test is considered 
diagnostic.
Definitive diagnosis: 
Isolation of C. trachomatis 
from appropriate 
specimen and confir­
mation of LGV 
immunotype, although 
such laboratory capabili­
ties are not widely 
available.
Recommended regimens: 
Doxycycline 100 mg PO 
twice a day for 14 days OR 
Tetracycline 500 mg PO 
4 times a day for 14 days.
Alternative regimens: 
Erythromycin 500 mg PO 
4 times a day for 14 days 
OR Sulphadiazine 1 g PO 
4 times a day for 14 days. 
Other sulphonamides can 
be used in equivalent doses.
Fluctuant lymph nodes should 
be aspirated as needed. Incision 
and drainage or excision of 
nodes will delay healing and 
are contraindicated.
Understand 
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disorders of upper 
genital tract of 
women. Many 
women have 
atypical or no 
symptoms. 
Symptoms include 
pain and tenderness 





are elevated white 




dysuria, pain with 
menses, fever, chills, 
and sometimes 
nausea and 
vomiting. Risk of 
PID increased 
by multiple sex 
partners, history 
of PID, or recent 
insertion of 
intrauterine device. 
PID can cause 
infertility, chronic 




By typical clinical 
symptoms if other 
serious conditions, 
such as acute appendi­
citis or ectopic 
pregnancy, can be 
excluded. Diagnosis 











of tubal exudate may 
be helpful.
Because the causative organisms are 
usually unknown at the start of 
therapy, use regimens effective against 
a broad range of pathogens.
Inpatient therapy:
Recommended regimens:
1. Ceftriaxone 500 mg IM once 
daily PLUS Doxycycline
100 mg PO or IV twice a day 
OR Tetracycline 500 mg PO 4 
times a day PLUS Metronidazole 
400-500 mg PO OR IV twice a 
day or Chloramphenicol 500 mg 
PO or IV 4 times a day.
2. Clindamycin 900 mg IV 8 hourly 
PLUS Gentamicin 1.5 mg/kg
IV 8 hourly.
S. Ciprofloxacin 500 mg PO twice 
a day OR Spectinomycin 1 g 
IM 4 times a day PLUS Doxycy- 
cline 100 mg PO or IV 2 times a 
day OR Tetracycline 500 mg 4 
times a day PLUS Metronidazole 
400-500 mg PO or IV twice a day 
OR Chloramphenicol 500 mg PO 
or IV 4 times a day.
Duration of therapy should be at 
least 2 days after the patient has 
improved. This treatment should 
be followed by either Doxycycline 
100 mg PO twice a day OR 
tetracycline 500 mg PO 4 times 
a day, both for 14 days.
Ambulatory therapy:
Recommended regimens:
Single-dose therapy for uncompli­
cated gonorrhea (e.g., Ceftriaxone) 
PLUS Doxycycline 100 mg PO twice 
a day for 14 days OR Ofloxacin,
400 mg PO twice a day for 14 days 
PLUS Metronidazole 500 mg PO 
twice a day for 14 days.
Alternative regimens (in absence 
of single-dose gonorrhea therapy) 
Trimethoprim (80 mg)/ 
Sulphamethoxazole (400 mg)
10 tablets PO once a day for S days 
and then 2 tablets twice a day for 
10 days PLUS Doxycycline 100 mg 
PO twice daily or Tetracycline 
500 mg PO 4 times a day for 14 days 
PLUS Metronidazole 400-500 mg 










you and your 
partner(s) are 
cured. Under­
stand how to take 
any prescribed 
oral medications. 










(Treponema Classical symptom is a 
pallidum) chancre (indurated painless
ulcer) at the site of exposure 
(e.g., vulva, cervix, penis, 
mouth, or anus). Internal 
lesions in women may not 
be detected. Lesion heals 
within a few weeks without 
treatment. Symptoms 
appear 10-90 days after 
infection. Differential 
diagnosis for all genital 
lesions should include 
syphilis.
If primary stage untreated, 
symptoms will appear in 
a few weeks, including a 
highly variable skin rash 
(especially on palms of 
hands and soles of feet), 
general lymph node 
enlargement, condyloma 
lata, hair loss, and fever 
and malaise. Symptoms 
last several weeks to months 
and will disappear even 
without treatment.
Latent:
No clinical signs of infec­
tion. Early syphilis (infec­
tious) defined as primary, 
secondary, or latent syphilis 
of less than 2 years’ dura­
tion. Late syphilis defined as 
latent syphilis of more than 
2 years’ duration or syphilis 
of unknown duration. 
Syphilis infection can cause 
congenital syphilis and late 
syphilis (including neuro­
syphilis, cardiovascular 




By identification of 
typical lesion(s) and 
either 1) a positive 
darkfield exam; 2) 
fluorescent antibody 
techniques in material 
from a chancre, regional 
lymph node, or other 
lesion; 3) the presence 
of a serologic test for 
syphilis (STS) titer at 
least four-fold greater 
than the last; or 4) 
patient’s exposure to 
syphilis within 90 days 
of lesion onset.
Secondary stage:
Diagnosis through typical 
clinical presentation of 
symptoms and a strongly 
reactive STS. Condyloma 
lata will be darkfield 
positive.
Latent stage:
Periods of infection with 
strongly reactive STS, 




of T. pallidum  with 
darkfield microscopy or 
fluorescent antibody 
technique for primary 
and secondary syphilis. 
No definitive diagnosis 
for latent syphilis.
Early syphilis (primary, second­
ary, or latent syphilis o f  not more 
than 2  years’ duration):
Recommended regimen: 
Benzathine penicillin 
G 2.4 million units IM 
once (often given as two 
injections at separate sites).
Alternative regimen:
Aqueous procaine penicillin 
G 1.2 million units IM daily 
for 10 consecutive days.
Late latent and late benign 
syphilis (latent syphilis o f  
indeterminate length or o f  
more than 2  years’ duration):
Recommended regimen: 
Benzathine penicillin G 7.2 
million units total, adminis­
tered as 2.4 million units 
IM given 1 week apart for 
3 consecutive weeks.
Alternative regimen:
Aqueous procaine penicillin 
G 1.2 million units IM daily 
for 20 consecutive days.
Neurosyphilis:
Recommended regimen: 
Aqueous crystalline penicillin 
G 12—24 million units total, 
administered as 2—4 million 
units every 4 hours IV for 
14 days.
Alternative regimen:
Aqueous procaine penicillin 
G 1.2 million units IM daily, 
A N D  probenecid 500 mg 
PO 4 times a day, both for 
10-14 days.
Penicillin-allergic patients: 
Doxycycline 100 mg PO 2 
times a day for 14 days (if early 




Erythromycin 500 mg 
PO 4 times a day for 14 days.
Obtain testing 




















Reproductive Health Epidemiology Series
Disease
(Pathogen)






green or yellow 
vaginal discharge, 
with foul odor. 
Itching, erythema, 
edema, pain on 
urination, and pain 
on intercourse also 
may occur. Some 
women may have 
no symptoms. Men 
are usually without 
symptoms, but may 
have urethritis, 
balanitis, cutaneous 
lesions on penis, pain 




Diagnosis when a vaginal 
culture or fluorescent 
antibody is positive for 
T. vaginalis OR typical 
motile trichomonads 
are identified in a saline 
wet mount of vaginal 
discharge. Trichomonads 
found by Pap smear are 
not diagnostic of active 
infection.
Recommended regimens: 
Metronidazole 2 g PO once.
Alternative regimen: 
Metronidazole 400-500 mg 
PO twice a day for 7 days.
Metronidazole is contraindi­
cated in the first trimester 
of pregnancy but may be 
used during the second and 
third trimesters. There is no 
evidence that other 5-nitro- 
imidazoles are superior 
to metronidazole, but they 
may be used when dictated 
by availability. Asymptomatic 
women should be treated 
with the same regimen as 
symptomatic women.
OR Sulphadiazine 1 g PO 4 
times a day for 14 days.
Other sulphonamides can 
be used in equivalent doses.
Fluctuant lymph nodes should 
be aspirated as needed. Incision 
and drainage or excision of 
nodes will delay healing and 
are contraindicated.
Understand how 




to prevent future 
infections. Avoid 
drinking alcohol 








Recommended regimens: Understand how
Miconazole or Clotrimazole, to take or use
200 mg intravaginally any prescribed
daily for 3 days medications.
OR Clotrimazole 500 mg Wear a sanitary
intravaginally once, pad to protect
OR Nystatin 100,000 units clothing and









Candida are normal 
flora of skin and 




varies from no signs or 
symptoms to itching, 
irritation, or pain of 
the external genitalia. 
Type of symptoms 
does not distinguish 
microbial etiology. 
Men may develop 
urethritis, balanitis, 







By typical clinical 
symptoms of vulvo­
vaginitis and microscopic 
identification of yeast 
forms or hyphae in 




By positive culture for 
C. albicans (or other 
Candida species) in 
symptomatic women. 
Cultures may detect 
clinically insignificant 
infections (should not 
be treated) and are not 
recommended.
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Ap p e n d ix  B. Ev a l u a t i n g  D i a g n o s t i c  Te s t s
Adapted from: Greenberg RS, Daniels SR, Flanders W D , Eley JW, Boring JR. Medical 
epidemiology. 2nd ed. Stamford (CT): A ppleton and Lange; 1996. p. 75—85.
Hennekens C H , Buring JE. Screening. In: M ayrent SL, editor. Epidemiology in medicine. 
Boston: Little, Brown and Company; 1987. p. 327—47.
The purpose of diagnostic testing is to determine the presence or 
absence of a particular condition. The process o f testing to detect 
disease at its earliest stages among asymptomatic people in the general 
population is called screening. At other times, diagnostic tests are 
used in order to confirm a diagnosis among people with existing signs 
or symptoms of illness. In general, diagnostic and screening tests are 
evaluated by calculating their sensitivity or specificity. Sensitivity 
indicates how good a test is at identifying the disease, and specificity 
indicates how good a test is at identifying those who are free of disease.
Consider a test that has only positive or negative results. When 
evaluating a diagnostic test, four situations are possible: a) a true 
positive result, where the test is positive and the patient has the 
disease; b) a false positive result, where the test is positive but the 
patient does not have the disease; c) a false negative result, where the 
test is negative but the patient has the disease; and d) a true negative 
result, where the test is negative and the patient does not have the 
disease (see diagram below). The best diagnostic tests are those with 
few false positives and false negatives (32).














Sensitivity and specificity are measures used to describe the accuracy 
of a test.
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Sensitivity
Definition. Sensitivity is defined as the percentage o f people with the 
disease of interest who have positive test results.
True positives
Sensitivity =  x 100




Use and Interpretation. The greater the sensitivity of a test, the more 
likely that the test will detect persons with the disease of interest. Tests 
with high sensitivity are useful clinically to rule out a disease; when 
sensitivity is high, there can be confidence in a negative test result.
Specificity
Definition. Specificity is defined as the percentage o f people without 
the disease o f interest who have negative test results.
True negatives
Specificity = ------------------------------------------  x 100
False positives + True negatives
d
=  x 100
b + d
Use and Interpretation. The greater the specificity, the more likely 
that people without the disease o f interest will not be identified by 
the test. Thus, highly specific tests are often used to confirm the 
presence of a disease.
The value of a diagnostic test depends not only on its sensitivity and 
specificity, but also on the prevalence of the disease in the population 
being tested. As the prevalence o f a disease decreases, it becomes less 
likely that someone with a positive test actually has the disease and 
more likely that the test represents a false positive. Therefore, the rarer 
a disease, the more specific a test must be in order to be clinically 
useful. O n the other hand, the more common a disease, the more 
sensitive the test must be to be clinically useful. Otherwise, a negative 
test is likely to represent a false negative.
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Prevalence
Definition. The prevalence of a disease is defined as the number of 
existing cases of the disease per total population at a given point in time.
Prevalence = Number o f existing cases of the disease of interest
---------------------------------------------------------------- x 100
Total population
= a + c
_____________  x 100
a + b + c + d
Use and Interpretation. Prevalence can be thought of as the status 
of the disease in a population at a point in time and is sometimes 
referred to as point prevalence. The denominator includes the total 
population (for example, all women of reproductive age, both with 
and without the disease o f interest).
The predictive value positive and negative are measures that 
directly address the estimation o f probability of disease. Because it 
incorporates information on both the test and the population being 
tested, predictive value is a good measure o f overall clinical usefulness.
predictive value positive
Definition. The predictive value positive (PV+) is the probability that 
a person with a positive test result actually has the disease.
True positives
------------------------------------------  x 100
PV+ = True positives + False positives
a
--------- x 100
= a + b
Use and Interpretation. The PV+ is the proportion of people with 
positive test results who actually have the disease. This measure allows 
one to estimate how likely it is that the disease of interest is present if 
the test is positive.
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predictive value negative
Definition. The predictive value negative (PV-) is the probability that a 
person with a negative test result does not have the disease.
True negatives
PV - = -------------------------------------------  x 100
False negatives + True negatives
d= --------- x 100
c + d
Use and Interpretation. The PV - is the proportion of people with 
negative test results who are free of disease; in other words, it is the 
probability of the disease being absent if the test is negative.
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